<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Ther</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Ther</journal-id><journal-title-group><journal-title>Diabetes Therapy</journal-title></journal-title-group><issn pub-type="ppub">1869-6953</issn><issn pub-type="epub">1869-6961</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24604395</article-id><article-id pub-id-type="pmc">4065285</article-id><article-id pub-id-type="publisher-id">59</article-id><article-id pub-id-type="doi">10.1007/s13300-014-0059-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Odawara</surname><given-names>Masato</given-names></name><address><phone>+81-3-33426111</phone><email>odawara@tokyo-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Hamada</surname><given-names>Izumi</given-names></name><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="Aff2"></xref></contrib><aff id="Aff1"><label></label>The Third Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan </aff><aff id="Aff2"><label></label>Novartis Pharma K.K., Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><volume>5</volume><issue>1</issue><fpage>169</fpage><lpage>181</lpage><history><date date-type="received"><day>23</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>© The Author(s) 2014</copyright-statement></permissions><abstract id="Abs1"><sec><title><offsets xml_i="2417" xml_f="2429" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="2440" xml_f="2652" txt_i="24" txt_f="236">The objective of this study was to evaluate the efficacy and safety of vildagliptin, a potent dipeptidyl peptidase-4 inhibitor, as an add-on to metformin in Japanese patients with type 2 diabetes mellitus (T2DM).</offsets></p></sec><sec><title><offsets xml_i="2674" xml_f="2681" txt_i="238" txt_f="245">Methods</offsets></title><p><offsets xml_i="2692" xml_f="2908" txt_i="246" txt_f="462">This multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-arm study compared vildagliptin 50 mg bid with placebo in T2DM patients who were inadequately controlled [glycosylated hemoglobin (HbA</offsets><sub><offsets xml_i="2913" xml_f="2915" txt_i="462" txt_f="464">1c</offsets></sub><offsets xml_i="2921" xml_f="3009" txt_i="464" txt_f="552">) 7.0–10.0%] on a stable daily dose of metformin monotherapy (250 mg bid or 500 mg bid).</offsets></p></sec><sec><title><offsets xml_i="3031" xml_f="3038" txt_i="554" txt_f="561">Results</offsets></title><p><offsets xml_i="3049" xml_f="3121" txt_i="562" txt_f="634">A total of 139 patients were randomized to receive either vildagliptin (</offsets><italic><offsets xml_i="3129" xml_f="3130" txt_i="634" txt_f="635">n</offsets></italic><offsets xml_i="3139" xml_f="3158" txt_i="635" txt_f="654"> = 69) or placebo (</offsets><italic><offsets xml_i="3166" xml_f="3167" txt_i="654" txt_f="655">n</offsets></italic><offsets xml_i="3176" xml_f="3309" txt_i="655" txt_f="788"> = 70). Patient demographics were comparable between the groups at baseline. After 12 weeks of treatment, adjusted mean change in HbA</offsets><sub><offsets xml_i="3314" xml_f="3316" txt_i="788" txt_f="790">1c</offsets></sub><offsets xml_i="3322" xml_f="3469" txt_i="790" txt_f="937"> was −1.1% in the vildagliptin group (baseline 8.0%) and −0.1% in the placebo group (baseline 8.0%), with a between-treatment difference of −1.0% (</offsets><italic><offsets xml_i="3477" xml_f="3478" txt_i="937" txt_f="938">P</offsets></italic><offsets xml_i="3487" xml_f="3547" txt_i="938" txt_f="995"> &lt; 0.001). Vildagliptin showed a similar reduction in HbA</offsets><sub><offsets xml_i="3552" xml_f="3554" txt_i="995" txt_f="997">1c</offsets></sub><offsets xml_i="3560" xml_f="3656" txt_i="997" txt_f="1093"> of −1.1% for both the subpopulations of patients receiving metformin 250 mg bid or 500 mg bid (</offsets><italic><offsets xml_i="3664" xml_f="3665" txt_i="1093" txt_f="1094">P</offsets></italic><offsets xml_i="3674" xml_f="3770" txt_i="1094" txt_f="1187"> &lt; 0.001 vs. baseline). Significantly more patients in the vildagliptin group achieved an HbA</offsets><sub><offsets xml_i="3775" xml_f="3777" txt_i="1187" txt_f="1189">1c</offsets></sub><offsets xml_i="3783" xml_f="3862" txt_i="1189" txt_f="1265"> target of ≤6.5% (30.9%) and &lt;7.0% (64.1%) compared with the placebo group (</offsets><italic><offsets xml_i="3870" xml_f="3871" txt_i="1265" txt_f="1266">P</offsets></italic><offsets xml_i="3880" xml_f="3994" txt_i="1266" txt_f="1377"> &lt; 0.001). The between-treatment difference in adjusted mean change in fasting plasma glucose was −1.6 mmol/L (</offsets><italic><offsets xml_i="4002" xml_f="4003" txt_i="1377" txt_f="1378">P</offsets></italic><offsets xml_i="4012" xml_f="4227" txt_i="1378" txt_f="1590"> &lt; 0.001) in favor of vildagliptin. Patients in the vildagliptin and placebo groups reported comparable incidences of adverse events (44.1% vs. 41.4%). No deaths or hypoglycemic events were reported in the study.</offsets></p></sec><sec><title><offsets xml_i="4249" xml_f="4260" txt_i="1592" txt_f="1603">Conclusions</offsets></title><p><offsets xml_i="4271" xml_f="4468" txt_i="1604" txt_f="1801">Vildagliptin 50 mg bid added to metformin improved glycemic control without any tolerability issues and hypoglycemia in Japanese patients with T2DM inadequately controlled on metformin monotherapy.</offsets></p></sec><sec><title><offsets xml_i="4490" xml_f="4523" txt_i="1803" txt_f="1836">Electronic supplementary material</offsets></title><p><offsets xml_i="4534" xml_f="4673" txt_i="1837" txt_f="1976">The online version of this article (doi:10.1007/s13300-014-0059-x) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antidiabetic drug</kwd><kwd>Dipeptidyl peptidase-4 inhibitor</kwd><kwd>Glycemic control</kwd><kwd>Metformin</kwd><kwd>Randomized trial</kwd><kwd>Type 2 diabetes mellitus</kwd><kwd>Vildagliptin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Healthcare 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="5197" xml_f="5209" txt_i="1985" txt_f="1997">Introduction</offsets></title><p><offsets xml_i="5220" xml_f="5385" txt_i="1998" txt_f="2163">In Japan, the estimated number of individuals with type 2 diabetes mellitus (T2DM) is approximately 7.1 million, which is the ninth largest prevalence in the world [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="5417" xml_f="5418" txt_i="2163" txt_f="2164">1</offsets></xref><offsets xml_i="5425" xml_f="5566" txt_i="2164" txt_f="2305">]. In recent years, the prevalence of T2DM in Japan has increased due to lifestyle changes, genetic predisposition, and an aging population [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="5598" xml_f="5599" txt_i="2305" txt_f="2306">2</offsets></xref><offsets xml_i="5606" xml_f="5608" txt_i="2306" txt_f="2308">, </offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="5640" xml_f="5641" txt_i="2308" txt_f="2309">3</offsets></xref><offsets xml_i="5648" xml_f="5751" txt_i="2309" txt_f="2412">]. Most of the Japanese T2DM patients are non-obese with an average body mass index (BMI) of 23–25 kg/m</offsets><sup><offsets xml_i="5756" xml_f="5757" txt_i="2412" txt_f="2413">2</offsets></sup><offsets xml_i="5763" xml_f="5855" txt_i="2413" txt_f="2505">, impaired insulin secretion plays a key role in the development of T2DM in these patients [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="5887" xml_f="5888" txt_i="2505" txt_f="2506">4</offsets></xref><offsets xml_i="5895" xml_f="5897" txt_i="2506" txt_f="2508">].</offsets></p><p><offsets xml_i="5904" xml_f="6061" txt_i="2509" txt_f="2666">Despite major advances in the management of T2DM and availability of a range of antidiabetic agents, evidence suggests that up to ~60% of patients in Japan [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="6093" xml_f="6094" txt_i="2666" txt_f="2667">5</offsets></xref><offsets xml_i="6101" xml_f="6173" txt_i="2667" txt_f="2739">] fail to achieve the recommended target of glycosylated hemoglobin (HbA</offsets><sub><offsets xml_i="6178" xml_f="6180" txt_i="2739" txt_f="2741">1c</offsets></sub><offsets xml_i="6186" xml_f="6205" txt_i="2741" txt_f="2757">) levels &lt;7.0% [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="6237" xml_f="6238" txt_i="2757" txt_f="2758">6</offsets></xref><offsets xml_i="6245" xml_f="6247" txt_i="2758" txt_f="2760">].</offsets></p><p><offsets xml_i="6254" xml_f="6499" txt_i="2761" txt_f="3006">Metformin is one of the commonly used oral antidiabetic agents (OADs) in Japan. Metformin improves blood glucose levels primarily by inhibiting hepatic glucose production and also improving insulin sensitivity in the liver and skeletal muscles [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="6531" xml_f="6532" txt_i="3006" txt_f="3007">7</offsets></xref><offsets xml_i="6539" xml_f="6851" txt_i="3007" txt_f="3319">]. However, due to the progressive nature of T2DM, long-term glycemic control is difficult to achieve with a single agent, thus often requiring addition of further agents. Addition of a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor with metformin is beneficial due to their complementary mechanisms of action [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="6883" xml_f="6884" txt_i="3319" txt_f="3320">8</offsets></xref><offsets xml_i="6891" xml_f="6893" txt_i="3320" txt_f="3322">].</offsets></p><p><offsets xml_i="6900" xml_f="7157" txt_i="3323" txt_f="3580">Vildagliptin, a potent and selective DPP-4 inhibitor, increases the active levels of incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby improving pancreatic α- and β-cell sensitivity to glucose [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="7189" xml_f="7190" txt_i="3580" txt_f="3581">9</offsets></xref><offsets xml_i="7197" xml_f="7298" txt_i="3581" txt_f="3682">]. In large-scale clinical trials, vildagliptin improved glycemic control when given as monotherapy [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="7331" xml_f="7333" txt_i="3682" txt_f="3684">10</offsets></xref><offsets xml_i="7340" xml_f="7376" txt_i="3684" txt_f="3720">] or in combination with metformin [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="7409" xml_f="7411" txt_i="3720" txt_f="3722">11</offsets></xref><offsets xml_i="7418" xml_f="7435" txt_i="3722" txt_f="3739">], sulfonylurea [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="7468" xml_f="7470" txt_i="3739" txt_f="3741">12</offsets></xref><offsets xml_i="7477" xml_f="7499" txt_i="3741" txt_f="3763">], thiazolidinedione [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="7532" xml_f="7534" txt_i="3763" txt_f="3765">13</offsets></xref><offsets xml_i="7541" xml_f="7555" txt_i="3765" txt_f="3779">] or insulin [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="7588" xml_f="7590" txt_i="3779" txt_f="3781">14</offsets></xref><offsets xml_i="7597" xml_f="7768" txt_i="3781" txt_f="3952">], with low risk of hypoglycemia and weight gain. Vildagliptin 50 mg bid showed notable improvement in blood glucose levels and better tolerability compared with placebo [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="7801" xml_f="7803" txt_i="3952" txt_f="3954">15</offsets></xref><offsets xml_i="7810" xml_f="7826" txt_i="3954" txt_f="3970">] or voglibose [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="7859" xml_f="7861" txt_i="3970" txt_f="3972">16</offsets></xref><offsets xml_i="7868" xml_f="8146" txt_i="3972" txt_f="4250">] in Japanese patients with T2DM inadequately controlled on diet and exercise. Combination therapy of vildagliptin with low-dose (500 mg bid) and high-dose (1,000 mg bid) metformin showed improved glycemic control compared with individual monotherapies in a large global study [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="8179" xml_f="8181" txt_i="4250" txt_f="4252">17</offsets></xref><offsets xml_i="8188" xml_f="8754" txt_i="4252" txt_f="4812">]. The high dose of metformin (&gt;750 mg/day) was approved in Japan in 2010. However, there are limited clinical data on the use of DPP-4 inhibitors in combination with metformin (&gt;750 mg/day) in Japanese patients with T2DM. The aim of the present study was to evaluate the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with T2DM inadequately controlled with metformin 500 or 1,000 mg/day. The study was conducted to support registration of the fixed-dose combination of vildagliptin and metformin for the treatment of T2DM in Japan.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="8815" xml_f="8836" txt_i="4814" txt_f="4835">Materials and Methods</offsets></title><sec id="Sec3"><title><offsets xml_i="8866" xml_f="8878" txt_i="4836" txt_f="4848">Study Design</offsets></title><p><offsets xml_i="8889" xml_f="9604" txt_i="4849" txt_f="5564">This was a 12-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study conducted across 20 centers in Japan in patients with T2DM inadequately controlled on metformin and diet/exercise. Following a screening period (visit 1), eligible patients who were on a stable daily dose of metformin (250 mg bid or 500 mg bid) for at least 10 weeks proceeded directly to randomization (baseline, visit 2) to receive either vildagliptin 50 mg bid or placebo as add-on to metformin in a 1:1 ratio. Patients taking OADs other than metformin were switched to either metformin 250 mg bid or 500 mg bid at the investigator’s discretion and were randomized after completing a 12-week run-in period (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="9636" xml_f="9637" txt_i="5564" txt_f="5565">1</offsets></xref><offsets xml_i="9644" xml_f="10141" txt_i="5565" txt_f="6062">). This was followed by three scheduled visits from baseline (weeks 4, 8, and 12) during which efficacy and tolerability were assessed. Randomization was stratified to adjust for metformin dose in 1:1 ratio in both the treatment groups. The dose of metformin remained unchanged throughout the study and no rescue medication (additional OADs or insulin) was allowed. Patients with unsatisfactory therapeutic effect [fasting plasma glucose (FPG) ≥15.0 mmol/L] were to be discontinued from the study.</offsets><fig id="Fig1"><label><offsets xml_i="10163" xml_f="10169" txt_i="6062" txt_f="6068">Fig. 1</offsets></label><caption><p><offsets xml_i="10189" xml_f="10201" txt_i="6068" txt_f="6080">Study design</offsets></p></caption><graphic xlink:href="13300_2014_59_Fig1_HTML" id="MO1"></graphic></fig></p></sec><sec id="Sec4"><title><offsets xml_i="10318" xml_f="10334" txt_i="6083" txt_f="6099">Study Population</offsets></title><p><offsets xml_i="10345" xml_f="10434" txt_i="6100" txt_f="6186">The study enrolled men and women with T2DM, aged ≥20 to &lt;75 years, BMI ≥20 to ≤35 kg/m</offsets><sup><offsets xml_i="10439" xml_f="10440" txt_i="6186" txt_f="6187">2</offsets></sup><offsets xml_i="10446" xml_f="10460" txt_i="6187" txt_f="6201">, baseline HbA</offsets><sub><offsets xml_i="10465" xml_f="10467" txt_i="6201" txt_f="6203">1c</offsets></sub><offsets xml_i="10473" xml_f="10715" txt_i="6203" txt_f="6445"> values ≥7.0% to ≤10.0%, who were inadequately controlled on diet, exercise and metformin monotherapy. The patients were required to be on a stable daily dose of metformin 250 mg bid or 500 mg bid for at least 10 weeks prior to randomization.</offsets></p><p><offsets xml_i="10722" xml_f="11384" txt_i="6446" txt_f="7102">The key exclusion criteria included history of type 1 diabetes, diabetes due to pancreatic injury or secondary forms, acute metabolic complications such as ketoacidosis or lactic acidosis, liver diseases such as cirrhosis or hepatitis, impaired renal function, congestive heart failure (New York Heart Association Class III or IV), myocardial infarction, stroke or transient ischemic attacks in the past 6 months. Patients with any of the following laboratory abnormalities at baseline were excluded: FPG ≥15 mmol/L; alanine transaminase, aspartate transaminase, or total bilirubin &gt;2 times the upper limit of normal; and fasting triglycerides &gt;5.7 mmol/L.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="11416" xml_f="11447" txt_i="7104" txt_f="7135">Study Endpoints and Assessments</offsets></title><p><offsets xml_i="11458" xml_f="11509" txt_i="7136" txt_f="7187">The primary efficacy endpoint was the change in HbA</offsets><sub><offsets xml_i="11514" xml_f="11516" txt_i="7187" txt_f="7189">1c</offsets></sub><offsets xml_i="11522" xml_f="11624" txt_i="7189" txt_f="7291"> from baseline to week 12 or the study endpoint. The key secondary efficacy endpoint was change in HbA</offsets><sub><offsets xml_i="11629" xml_f="11631" txt_i="7291" txt_f="7293">1c</offsets></sub><offsets xml_i="11637" xml_f="11880" txt_i="7293" txt_f="7536"> from baseline to study endpoint within subpopulations of patients treated with vildagliptin and metformin (250 mg bid or 500 mg bid). Other secondary efficacy endpoints included percentage of patients (responder rate) achieving predefined HbA</offsets><sub><offsets xml_i="11885" xml_f="11887" txt_i="7536" txt_f="7538">1c</offsets></sub><offsets xml_i="11893" xml_f="12023" txt_i="7538" txt_f="7665"> targets (≤6.5%, &lt;7.0%, and reductions of ≥0.5% and ≥1.0%) and change in FPG levels after 12 weeks of treatment. Changes in HbA</offsets><sub><offsets xml_i="12028" xml_f="12030" txt_i="7665" txt_f="7667">1c</offsets></sub><offsets xml_i="12036" xml_f="12176" txt_i="7667" txt_f="7807"> (reported in National Glycohemoglobin Standardization Program units) and FPG were assessed at each scheduled visit (weeks 0, 4, 8, and 12).</offsets></p><p><offsets xml_i="12183" xml_f="13365" txt_i="7808" txt_f="8987">Adverse events (AEs) and serious AEs (SAEs) were recorded at each visit, and were assessed for severity, duration, and suspected relationship to the study drug. Standard hematology, biochemistry, liver function tests, urinalysis, vital signs, and body weight were measured at the screening visit and at weeks 0, 4, 8, and 12. Electrocardiograms were recorded at screening and at the last study visit (week 12). Fasting lipid profile was assessed at baseline and at the last study visit. All the patients were provided with a calibrated home glucose monitor and were instructed regarding its use. The patients were educated regarding hypoglycemic symptoms, possible triggers and were asked to record hypoglycemic event in a study diary. Hypoglycemia was defined as symptoms suggestive of hypoglycemia that was further confirmed by a self-monitored blood glucose measurement of &lt;3.1 mmol/L. The event was considered grade 1 if the patient was able to initiate self-treatment, and grade 2 if the patient required assistance of another person or hospitalization. All the laboratory assessments were performed at a central laboratory (Mitsubishi Chemical Medience Corporation, Japan).</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="13397" xml_f="13417" txt_i="8989" txt_f="9009">Statistical Analysis</offsets></title><p><offsets xml_i="13428" xml_f="13734" txt_i="9010" txt_f="9316">A total of 136 patients (68 patients per group) were to be randomized (1:1) to achieve a target sample size of 128 patients (64 per group), assuming a dropout rate of 5%. This sample size would ensure at least 92% power to detect a clinically relevant between-group difference of 0.6% absolute units in HbA</offsets><sub><offsets xml_i="13739" xml_f="13741" txt_i="9316" txt_f="9318">1c</offsets></sub><offsets xml_i="13747" xml_f="13928" txt_i="9318" txt_f="9499"> change from baseline, assuming a one-sided significance level of 0.025, to demonstrate the superiority of vildagliptin 50 mg bid over placebo as add-on to metformin in reducing HbA</offsets><sub><offsets xml_i="13933" xml_f="13935" txt_i="9499" txt_f="9501">1c</offsets></sub><offsets xml_i="13941" xml_f="14342" txt_i="9501" txt_f="9902"> after 12 weeks of treatment. Moreover, randomization was stratified by metformin dose to ensure that patients on metformin 250 mg bid and 500 mg bid each constituted ~50% of the randomized population. The planned sample size of 136 patients (34 patients in each metformin subpopulation in the vildagliptin group) would provide at least 90% power to detect a statistically significant reduction in HbA</offsets><sub><offsets xml_i="14347" xml_f="14349" txt_i="9902" txt_f="9904">1c</offsets></sub><offsets xml_i="14355" xml_f="14482" txt_i="9904" txt_f="10031"> of 0.6% from baseline in each metformin subgroup (250 mg bid or 500 mg bid), assuming a one-sided significance level of 0.025.</offsets></p><p><offsets xml_i="14489" xml_f="14743" txt_i="10032" txt_f="10286">The primary and secondary efficacy analyses were based on the full analysis set, which included all randomized patients who received at least one dose of the study drug and had at least one post-randomization efficacy parameter assessment. Changes in HbA</offsets><sub><offsets xml_i="14748" xml_f="14750" txt_i="10286" txt_f="10288">1c</offsets></sub><offsets xml_i="14756" xml_f="14945" txt_i="10288" txt_f="10477"> and FPG from baseline to study endpoint were analyzed using the analysis of covariance model (ANCOVA), with treatment groups and metformin dose as classification variables and baseline HbA</offsets><sub><offsets xml_i="14950" xml_f="14952" txt_i="10477" txt_f="10479">1c</offsets></sub><offsets xml_i="14958" xml_f="15159" txt_i="10479" txt_f="10680"> as covariate. The study endpoint is the final available post-randomization assessment value at any visit (scheduled or unscheduled) up to final visit (week 12). The between-treatment difference in HbA</offsets><sub><offsets xml_i="15164" xml_f="15166" txt_i="10680" txt_f="10682">1c</offsets></sub><offsets xml_i="15172" xml_f="15226" txt_i="10682" txt_f="10736"> and FPG was also analyzed using ANCOVA. Change in HbA</offsets><sub><offsets xml_i="15231" xml_f="15233" txt_i="10736" txt_f="10738">1c</offsets></sub><offsets xml_i="15239" xml_f="15336" txt_i="10738" txt_f="10835"> from baseline to study endpoint within the metformin subpopulations was analyzed using a paired </offsets><italic><offsets xml_i="15344" xml_f="15345" txt_i="10835" txt_f="10836">t</offsets></italic><offsets xml_i="15354" xml_f="15540" txt_i="10836" txt_f="11022"> test. Missing data because of early discontinuation were handled using the last observation carried forward method. The impact of various baseline characteristics (age, gender, BMI, HbA</offsets><sub><offsets xml_i="15545" xml_f="15548" txt_i="11022" txt_f="11025">1c,</offsets></sub><offsets xml_i="15554" xml_f="15589" txt_i="11025" txt_f="11060"> and FPG) on absolute change in HbA</offsets><sub><offsets xml_i="15594" xml_f="15596" txt_i="11060" txt_f="11062">1c</offsets></sub><offsets xml_i="15602" xml_f="15705" txt_i="11062" txt_f="11165"> from baseline to endpoint was analyzed using descriptive statistics. The proportion of responders (HbA</offsets><sub><offsets xml_i="15710" xml_f="15712" txt_i="11165" txt_f="11167">1c</offsets></sub><offsets xml_i="15718" xml_f="15741" txt_i="11167" txt_f="11190"> ≤6.5% at endpoint, HbA</offsets><sub><offsets xml_i="15746" xml_f="15748" txt_i="11190" txt_f="11192">1c</offsets></sub><offsets xml_i="15754" xml_f="15796" txt_i="11192" txt_f="11231"> &lt;7% at endpoint, and reductions in HbA</offsets><sub><offsets xml_i="15801" xml_f="15803" txt_i="11231" txt_f="11233">1c</offsets></sub><offsets xml_i="15809" xml_f="16442" txt_i="11233" txt_f="11866"> ≥0.5% and ≥1%) in each treatment group was computed and compared using the Chi-square test. The data analysis for this study was carried out using SAS software (version 9.2, SAS Institute Inc., Cary, NC, USA). The safety set consisted of all patients who received at least one dose of the study drug. Safety data were summarized descriptively by treatment. The incidences of treatment-emergent AEs were summarized by system organ class (SOC), preferred term (PT), severity, and relationship to the study drug. AEs were coded by primary SOC and PT according to Medical Dictionary for Drug Regulatory Activities (MedDRA version 15.1).</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="16474" xml_f="16507" txt_i="11868" txt_f="11901">Ethics and Good Clinical Practice</offsets></title><p><offsets xml_i="16518" xml_f="17051" txt_i="11902" txt_f="12435">The study protocol was reviewed and approved by the Independent Ethics Committee/Institutional Review Board at each center. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), the Helsinki Declaration of 1975, as revised in 2000 and 2008 and Good Clinical Practice guidelines. Informed consent was obtained from all patients for being included in the study. The study is registered with ClinicalTrials.gov, identifier: NCT01497522.</offsets></p></sec></sec><sec id="Sec8" sec-type="results"><title><offsets xml_i="17108" xml_f="17115" txt_i="12438" txt_f="12445">Results</offsets></title><sec id="Sec9"><title><offsets xml_i="17145" xml_f="17193" txt_i="12446" txt_f="12494">Patient Disposition and Baseline Characteristics</offsets></title><p><offsets xml_i="17204" xml_f="17250" txt_i="12495" txt_f="12541">Of the 139 randomized patients (vildagliptin, </offsets><italic><offsets xml_i="17258" xml_f="17259" txt_i="12541" txt_f="12542">n</offsets></italic><offsets xml_i="17268" xml_f="17284" txt_i="12542" txt_f="12558"> = 69; placebo, </offsets><italic><offsets xml_i="17292" xml_f="17293" txt_i="12558" txt_f="12559">n</offsets></italic><offsets xml_i="17302" xml_f="17357" txt_i="12559" txt_f="12614"> = 70), 133 patients (95.7%) completed the study (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="17389" xml_f="17390" txt_i="12614" txt_f="12615">2</offsets></xref><offsets xml_i="17397" xml_f="17518" txt_i="12615" txt_f="12736">). The primary reasons for discontinuation in the study were AEs (3 patients) and protocol deviations (2 patients) (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="17550" xml_f="17551" txt_i="12736" txt_f="12737">2</offsets></xref><offsets xml_i="17558" xml_f="17663" txt_i="12737" txt_f="12842">). Patient demographics and baseline characteristics were comparable between the treatment groups (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="17697" xml_f="17698" txt_i="12842" txt_f="12843">1</offsets></xref><offsets xml_i="17705" xml_f="17743" txt_i="12843" txt_f="12881">). Overall mean age, BMI, baseline HbA</offsets><sub><offsets xml_i="17748" xml_f="17750" txt_i="12881" txt_f="12883">1c</offsets></sub><offsets xml_i="17756" xml_f="17819" txt_i="12883" txt_f="12946">, baseline FPG, and duration of T2DM were 58.1 years, 25.6 kg/m</offsets><sup><offsets xml_i="17824" xml_f="17825" txt_i="12946" txt_f="12947">2</offsets></sup><offsets xml_i="17831" xml_f="18031" txt_i="12947" txt_f="13147">, 8.0%, 9.2 mmol/L, and 7.1 years, respectively. The patients were predominantly men (66.2%), and more patients were aged ≥65 years in the vildagliptin group (31.9%) than in the placebo group (22.9%).</offsets><fig id="Fig2"><label><offsets xml_i="18053" xml_f="18059" txt_i="13147" txt_f="13153">Fig. 2</offsets></label><caption><p><offsets xml_i="18079" xml_f="18098" txt_i="13153" txt_f="13172">Patient disposition</offsets></p></caption><graphic xlink:href="13300_2014_59_Fig2_HTML" id="MO2"></graphic></fig><table-wrap id="Tab1"><label><offsets xml_i="18212" xml_f="18219" txt_i="13173" txt_f="13180">Table 1</offsets></label><caption><p><offsets xml_i="18239" xml_f="18305" txt_i="13180" txt_f="13246">Patient demographics and baseline characteristics (randomized set)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="18384" xml_f="18393" txt_i="13247" txt_f="13256">Parameter</offsets></th><th align="left"><offsets xml_i="18415" xml_f="18440" txt_i="13256" txt_f="13281">Vildagliptin + metformin </offsets><italic><offsets xml_i="18448" xml_f="18449" txt_i="13281" txt_f="13282">n</offsets></italic><offsets xml_i="18458" xml_f="18463" txt_i="13282" txt_f="13287"> = 69</offsets></th><th align="left"><offsets xml_i="18485" xml_f="18505" txt_i="13287" txt_f="13307">Placebo + metformin </offsets><italic><offsets xml_i="18513" xml_f="18514" txt_i="13307" txt_f="13308">n</offsets></italic><offsets xml_i="18523" xml_f="18528" txt_i="13308" txt_f="13313"> = 70</offsets></th><th align="left"><offsets xml_i="18550" xml_f="18556" txt_i="13313" txt_f="13319">Total </offsets><italic><offsets xml_i="18564" xml_f="18565" txt_i="13319" txt_f="13320">N</offsets></italic><offsets xml_i="18574" xml_f="18580" txt_i="13320" txt_f="13326"> = 139</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="18626" xml_f="18636" txt_i="13326" txt_f="13336">Age, years</offsets></td><td char="(" align="char"><offsets xml_i="18667" xml_f="18678" txt_i="13337" txt_f="13348">58.7 (9.81)</offsets></td><td char="(" align="char"><offsets xml_i="18709" xml_f="18720" txt_i="13349" txt_f="13360">57.5 (9.15)</offsets></td><td char="(" align="char"><offsets xml_i="18751" xml_f="18762" txt_i="13361" txt_f="13372">58.1 (9.47)</offsets></td></tr><tr><td align="left"><offsets xml_i="18793" xml_f="18805" txt_i="13373" txt_f="13385"> ≥65 years, </offsets><italic><offsets xml_i="18813" xml_f="18814" txt_i="13385" txt_f="13386">n</offsets></italic><offsets xml_i="18823" xml_f="18827" txt_i="13386" txt_f="13390"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="18858" xml_f="18867" txt_i="13391" txt_f="13400">22 (31.9)</offsets></td><td char="(" align="char"><offsets xml_i="18898" xml_f="18907" txt_i="13401" txt_f="13410">16 (22.9)</offsets></td><td char="(" align="char"><offsets xml_i="18938" xml_f="18947" txt_i="13411" txt_f="13420">38 (27.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="18978" xml_f="18983" txt_i="13421" txt_f="13426">Men, </offsets><italic><offsets xml_i="18991" xml_f="18992" txt_i="13426" txt_f="13427">n</offsets></italic><offsets xml_i="19001" xml_f="19005" txt_i="13427" txt_f="13431"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="19036" xml_f="19045" txt_i="13432" txt_f="13441">44 (63.8)</offsets></td><td char="(" align="char"><offsets xml_i="19076" xml_f="19085" txt_i="13442" txt_f="13451">48 (68.6)</offsets></td><td char="(" align="char"><offsets xml_i="19116" xml_f="19125" txt_i="13452" txt_f="13461">92 (66.2)</offsets></td></tr><tr><td align="left"><offsets xml_i="19156" xml_f="19171" txt_i="13462" txt_f="13477">Body weight, kg</offsets></td><td char="(" align="char"><offsets xml_i="19202" xml_f="19214" txt_i="13478" txt_f="13490">67.9 (12.70)</offsets></td><td char="(" align="char"><offsets xml_i="19245" xml_f="19257" txt_i="13491" txt_f="13503">70.0 (13.02)</offsets></td><td char="(" align="char"><offsets xml_i="19288" xml_f="19300" txt_i="13504" txt_f="13516">68.9 (12.85)</offsets></td></tr><tr><td align="left"><offsets xml_i="19331" xml_f="19340" txt_i="13517" txt_f="13526">BMI, kg/m</offsets><sup><offsets xml_i="19345" xml_f="19346" txt_i="13526" txt_f="13527">2</offsets></sup><offsets xml_i="19352" xml_f="19353" txt_i="13527" txt_f="13528">
</offsets></td><td char="(" align="char"><offsets xml_i="19384" xml_f="19395" txt_i="13529" txt_f="13540">25.3 (3.56)</offsets></td><td char="(" align="char"><offsets xml_i="19426" xml_f="19437" txt_i="13541" txt_f="13552">25.9 (4.01)</offsets></td><td char="(" align="char"><offsets xml_i="19468" xml_f="19479" txt_i="13553" txt_f="13564">25.6 (3.79)</offsets></td></tr><tr><td align="left"><offsets xml_i="19510" xml_f="19513" txt_i="13565" txt_f="13568">HbA</offsets><sub><offsets xml_i="19518" xml_f="19520" txt_i="13568" txt_f="13570">1c</offsets></sub><offsets xml_i="19526" xml_f="19529" txt_i="13570" txt_f="13573">, %</offsets></td><td char="(" align="char"><offsets xml_i="19560" xml_f="19570" txt_i="13574" txt_f="13584">8.0 (0.83)</offsets></td><td char="(" align="char"><offsets xml_i="19601" xml_f="19611" txt_i="13585" txt_f="13595">8.0 (0.96)</offsets></td><td char="(" align="char"><offsets xml_i="19642" xml_f="19652" txt_i="13596" txt_f="13606">8.0 (0.90)</offsets></td></tr><tr><td align="left"><offsets xml_i="19683" xml_f="19689" txt_i="13607" txt_f="13613"> ≤8%, </offsets><italic><offsets xml_i="19697" xml_f="19698" txt_i="13613" txt_f="13614">n</offsets></italic><offsets xml_i="19707" xml_f="19711" txt_i="13614" txt_f="13618"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="19742" xml_f="19751" txt_i="13619" txt_f="13628">40 (58.0)</offsets></td><td char="(" align="char"><offsets xml_i="19782" xml_f="19791" txt_i="13629" txt_f="13638">40 (57.1)</offsets></td><td char="(" align="char"><offsets xml_i="19822" xml_f="19831" txt_i="13639" txt_f="13648">80 (57.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="19862" xml_f="19877" txt_i="13649" txt_f="13661"> &gt;8 to ≤9%, </offsets><italic><offsets xml_i="19885" xml_f="19886" txt_i="13661" txt_f="13662">n</offsets></italic><offsets xml_i="19895" xml_f="19899" txt_i="13662" txt_f="13666"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="19930" xml_f="19939" txt_i="13667" txt_f="13676">17 (24.6)</offsets></td><td char="(" align="char"><offsets xml_i="19970" xml_f="19979" txt_i="13677" txt_f="13686">14 (20.0)</offsets></td><td char="(" align="char"><offsets xml_i="20010" xml_f="20019" txt_i="13687" txt_f="13696">31 (22.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="20050" xml_f="20059" txt_i="13697" txt_f="13703"> &gt;9%, </offsets><italic><offsets xml_i="20067" xml_f="20068" txt_i="13703" txt_f="13704">n</offsets></italic><offsets xml_i="20077" xml_f="20081" txt_i="13704" txt_f="13708"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="20112" xml_f="20121" txt_i="13709" txt_f="13718">12 (17.4)</offsets></td><td char="(" align="char"><offsets xml_i="20152" xml_f="20161" txt_i="13719" txt_f="13728">16 (22.9)</offsets></td><td char="(" align="char"><offsets xml_i="20192" xml_f="20201" txt_i="13729" txt_f="13738">28 (20.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="20232" xml_f="20243" txt_i="13739" txt_f="13750">FPG, mmol/L</offsets></td><td char="(" align="char"><offsets xml_i="20274" xml_f="20284" txt_i="13751" txt_f="13761">9.1 (1.80)</offsets></td><td char="(" align="char"><offsets xml_i="20315" xml_f="20325" txt_i="13762" txt_f="13772">9.3 (2.40)</offsets></td><td char="(" align="char"><offsets xml_i="20356" xml_f="20366" txt_i="13773" txt_f="13783">9.2 (2.12)</offsets></td></tr><tr><td align="left"><offsets xml_i="20397" xml_f="20411" txt_i="13784" txt_f="13798"> ≥8.9 mmol/L, </offsets><italic><offsets xml_i="20419" xml_f="20420" txt_i="13798" txt_f="13799">n</offsets></italic><offsets xml_i="20429" xml_f="20433" txt_i="13799" txt_f="13803"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="20464" xml_f="20473" txt_i="13804" txt_f="13813">28 (40.6)</offsets></td><td char="(" align="char"><offsets xml_i="20504" xml_f="20513" txt_i="13814" txt_f="13823">36 (51.4)</offsets></td><td char="(" align="char"><offsets xml_i="20544" xml_f="20553" txt_i="13824" txt_f="13833">64 (46.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="20584" xml_f="20607" txt_i="13834" txt_f="13857">Duration of T2DM, years</offsets></td><td char="(" align="char"><offsets xml_i="20638" xml_f="20648" txt_i="13858" txt_f="13868">7.2 (6.18)</offsets></td><td char="(" align="char"><offsets xml_i="20679" xml_f="20689" txt_i="13869" txt_f="13879">7.0 (5.92)</offsets></td><td char="(" align="char"><offsets xml_i="20720" xml_f="20730" txt_i="13880" txt_f="13890">7.1 (6.03)</offsets></td></tr><tr><td align="left"><offsets xml_i="20761" xml_f="20791" txt_i="13891" txt_f="13921">Metformin total daily dose, mg</offsets></td><td char="(" align="char"><offsets xml_i="20822" xml_f="20836" txt_i="13922" txt_f="13936">753.6 (251.81)</offsets></td><td char="(" align="char"><offsets xml_i="20867" xml_f="20881" txt_i="13937" txt_f="13951">750.0 (251.81)</offsets></td><td char="(" align="char"><offsets xml_i="20912" xml_f="20926" txt_i="13952" txt_f="13966">751.8 (250.90)</offsets></td></tr><tr><td align="left"><offsets xml_i="20957" xml_f="20981" txt_i="13967" txt_f="13991"> Metformin ≤500 mg/day, </offsets><italic><offsets xml_i="20989" xml_f="20990" txt_i="13991" txt_f="13992">n</offsets></italic><offsets xml_i="20999" xml_f="21003" txt_i="13992" txt_f="13996"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="21034" xml_f="21043" txt_i="13997" txt_f="14006">34 (49.3)</offsets></td><td char="(" align="char"><offsets xml_i="21074" xml_f="21083" txt_i="14007" txt_f="14016">35 (50.0)</offsets></td><td char="(" align="char"><offsets xml_i="21114" xml_f="21123" txt_i="14017" txt_f="14026">69 (49.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="21154" xml_f="21181" txt_i="14027" txt_f="14051"> Metformin &gt;500 mg/day, </offsets><italic><offsets xml_i="21189" xml_f="21190" txt_i="14051" txt_f="14052">n</offsets></italic><offsets xml_i="21199" xml_f="21203" txt_i="14052" txt_f="14056"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="21234" xml_f="21243" txt_i="14057" txt_f="14066">35 (50.7)</offsets></td><td char="(" align="char"><offsets xml_i="21274" xml_f="21283" txt_i="14067" txt_f="14076">35 (50.0)</offsets></td><td char="(" align="char"><offsets xml_i="21314" xml_f="21323" txt_i="14077" txt_f="14086">70 (50.4)</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="21366" xml_f="21392" txt_i="14087" txt_f="14113">eGFR (MDRD), mL/min/1.73 m</offsets><sup><offsets xml_i="21397" xml_f="21398" txt_i="14113" txt_f="14114">2</offsets></sup><offsets xml_i="21404" xml_f="21406" txt_i="14114" txt_f="14116">, </offsets><italic><offsets xml_i="21414" xml_f="21415" txt_i="14116" txt_f="14117">n</offsets></italic><offsets xml_i="21424" xml_f="21428" txt_i="14117" txt_f="14121"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="21459" xml_f="21474" txt_i="14122" txt_f="14134"> Normal, &gt;80</offsets></td><td char="(" align="char"><offsets xml_i="21505" xml_f="21514" txt_i="14135" txt_f="14144">66 (95.7)</offsets></td><td char="(" align="char"><offsets xml_i="21545" xml_f="21554" txt_i="14145" txt_f="14154">64 (91.4)</offsets></td><td char="(" align="char"><offsets xml_i="21585" xml_f="21595" txt_i="14155" txt_f="14165">130 (93.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="21626" xml_f="21643" txt_i="14166" txt_f="14183"> Mild, ≥50 to ≤80</offsets></td><td char="(" align="char"><offsets xml_i="21674" xml_f="21681" txt_i="14184" txt_f="14191">3 (4.3)</offsets></td><td char="(" align="char"><offsets xml_i="21712" xml_f="21719" txt_i="14192" txt_f="14199">6 (8.6)</offsets></td><td char="(" align="char"><offsets xml_i="21750" xml_f="21757" txt_i="14200" txt_f="14207">9 (6.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="21788" xml_f="21812" txt_i="14208" txt_f="14229"> Moderate, ≥30 to &lt;50</offsets></td><td char="(" align="char"><offsets xml_i="21843" xml_f="21850" txt_i="14230" txt_f="14237">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="21881" xml_f="21888" txt_i="14238" txt_f="14245">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="21919" xml_f="21926" txt_i="14246" txt_f="14253">0 (0.0)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="21972" xml_f="22048" txt_i="14254" txt_f="14330">Values are expressed as mean (standard deviation) unless specified otherwise</offsets></p><p><offsets xml_i="22055" xml_f="22056" txt_i="14331" txt_f="14332">
</offsets><italic><offsets xml_i="22064" xml_f="22067" txt_i="14332" txt_f="14335">BMI</offsets></italic><offsets xml_i="22076" xml_f="22094" txt_i="14335" txt_f="14353"> body mass index, </offsets><italic><offsets xml_i="22102" xml_f="22106" txt_i="14353" txt_f="14357">eGFR</offsets></italic><offsets xml_i="22115" xml_f="22154" txt_i="14357" txt_f="14396"> estimated glomerular filtration rate, </offsets><italic><offsets xml_i="22162" xml_f="22165" txt_i="14396" txt_f="14399">FPG</offsets></italic><offsets xml_i="22174" xml_f="22199" txt_i="14399" txt_f="14424"> fasting plasma glucose, </offsets><italic><offsets xml_i="22207" xml_f="22210" txt_i="14424" txt_f="14427">HbA</offsets></italic><offsets xml_i="22219" xml_f="22220" txt_i="14427" txt_f="14428">
</offsets><sub><italic><offsets xml_i="22233" xml_f="22235" txt_i="14428" txt_f="14430">1c</offsets></italic></sub><offsets xml_i="22250" xml_f="22276" txt_i="14430" txt_f="14456"> glycosylated hemoglobin, </offsets><italic><offsets xml_i="22284" xml_f="22288" txt_i="14456" txt_f="14460">MDRD</offsets></italic><offsets xml_i="22297" xml_f="22337" txt_i="14460" txt_f="14500"> modification of diet in renal disease, </offsets><italic><offsets xml_i="22345" xml_f="22349" txt_i="14500" txt_f="14504">OADs</offsets></italic><offsets xml_i="22358" xml_f="22384" txt_i="14504" txt_f="14530"> oral antidiabetic drugs, </offsets><italic><offsets xml_i="22392" xml_f="22396" txt_i="14530" txt_f="14534">T2DM</offsets></italic><offsets xml_i="22405" xml_f="22430" txt_i="14534" txt_f="14559"> type 2 diabetes mellitus</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title><offsets xml_i="22498" xml_f="22506" txt_i="14562" txt_f="14570">Efficacy</offsets></title><p><offsets xml_i="22517" xml_f="22539" txt_i="14571" txt_f="14593">The mean change in HbA</offsets><sub><offsets xml_i="22544" xml_f="22546" txt_i="14593" txt_f="14595">1c</offsets></sub><offsets xml_i="22552" xml_f="22651" txt_i="14595" txt_f="14694"> during the 12 weeks of treatment was consistently lower with vildagliptin than with placebo (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="22683" xml_f="22684" txt_i="14694" txt_f="14695">3</offsets></xref><offsets xml_i="22691" xml_f="22745" txt_i="14695" txt_f="14749">a). The overall adjusted mean change (AM∆) ± SE in HbA</offsets><sub><offsets xml_i="22750" xml_f="22752" txt_i="14749" txt_f="14751">1c</offsets></sub><offsets xml_i="22758" xml_f="22952" txt_i="14751" txt_f="14945"> was −1.1 ± 0.06% in the vildagliptin group (baseline 8.0%) and −0.1 ± 0.06% in the placebo group (baseline 8.0%), with a statistically significant between-treatment difference of −1.0 ± 0.09% (</offsets><italic><offsets xml_i="22960" xml_f="22961" txt_i="14945" txt_f="14946">P</offsets></italic><offsets xml_i="22970" xml_f="23014" txt_i="14946" txt_f="14987"> &lt; 0.001) in favor of vildagliptin (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="23046" xml_f="23047" txt_i="14987" txt_f="14988">3</offsets></xref><offsets xml_i="23054" xml_f="23140" txt_i="14988" txt_f="15074">b). Vildagliptin also showed statistically significant reductions from baseline in HbA</offsets><sub><offsets xml_i="23145" xml_f="23147" txt_i="15074" txt_f="15076">1c</offsets></sub><offsets xml_i="23153" xml_f="23238" txt_i="15076" txt_f="15161"> for subpopulations of patients receiving metformin 250 mg bid and 500 mg bid (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="23272" xml_f="23273" txt_i="15161" txt_f="15162">2</offsets></xref><offsets xml_i="23280" xml_f="23341" txt_i="15162" txt_f="15223">). Significantly more patients with vildagliptin achieved HbA</offsets><sub><offsets xml_i="23346" xml_f="23348" txt_i="15223" txt_f="15225">1c</offsets></sub><offsets xml_i="23354" xml_f="23424" txt_i="15225" txt_f="15292"> targets of ≤6.5% (30.9%) and &lt;7.0% (64.1%) compared with placebo (</offsets><italic><offsets xml_i="23432" xml_f="23433" txt_i="15292" txt_f="15293">P</offsets></italic><offsets xml_i="23442" xml_f="23526" txt_i="15293" txt_f="15374"> &lt; 0.001). A higher proportion of patients in the vildagliptin group achieved HbA</offsets><sub><offsets xml_i="23531" xml_f="23533" txt_i="15374" txt_f="15376">1c</offsets></sub><offsets xml_i="23539" xml_f="23595" txt_i="15376" txt_f="15432"> reductions of ≥1% and ≥0.5% than in the placebo group (</offsets><italic><offsets xml_i="23603" xml_f="23604" txt_i="15432" txt_f="15433">P</offsets></italic><offsets xml_i="23613" xml_f="23633" txt_i="15433" txt_f="15450"> &lt; 0.001) (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="23667" xml_f="23668" txt_i="15450" txt_f="15451">3</offsets></xref><offsets xml_i="23675" xml_f="23677" txt_i="15451" txt_f="15453">).</offsets><fig id="Fig3"><label><offsets xml_i="23699" xml_f="23705" txt_i="15453" txt_f="15459">Fig. 3</offsets></label><caption><p><offsets xml_i="23725" xml_f="23726" txt_i="15459" txt_f="15460">
</offsets><bold><offsets xml_i="23732" xml_f="23733" txt_i="15460" txt_f="15461">a</offsets></bold><offsets xml_i="23740" xml_f="23774" txt_i="15461" txt_f="15495"> Mean glycosylated hemoglobin (HbA</offsets><sub><offsets xml_i="23779" xml_f="23781" txt_i="15495" txt_f="15497">1c</offsets></sub><offsets xml_i="23787" xml_f="23833" txt_i="15497" txt_f="15543">) by treatment and visit (full analysis set). </offsets><bold><offsets xml_i="23839" xml_f="23840" txt_i="15543" txt_f="15544">b</offsets></bold><offsets xml_i="23847" xml_f="23875" txt_i="15544" txt_f="15572"> Adjusted mean change in HbA</offsets><sub><offsets xml_i="23880" xml_f="23882" txt_i="15572" txt_f="15574">1c</offsets></sub><offsets xml_i="23888" xml_f="23936" txt_i="15574" txt_f="15622"> from baseline to endpoint (full analysis set). </offsets><italic><offsets xml_i="23944" xml_f="23946" txt_i="15622" txt_f="15624">BL</offsets></italic><offsets xml_i="23955" xml_f="23966" txt_i="15624" txt_f="15635"> baseline, </offsets><italic><offsets xml_i="23974" xml_f="23976" txt_i="15635" txt_f="15637">EP</offsets></italic><offsets xml_i="23985" xml_f="23996" txt_i="15637" txt_f="15648"> endpoint, </offsets><italic><offsets xml_i="24004" xml_f="24006" txt_i="15648" txt_f="15650">SE</offsets></italic><offsets xml_i="24015" xml_f="24033" txt_i="15650" txt_f="15668"> standard error. *</offsets><italic><offsets xml_i="24041" xml_f="24042" txt_i="15668" txt_f="15669">P</offsets></italic><offsets xml_i="24051" xml_f="24062" txt_i="15669" txt_f="15677"> &lt; 0.001</offsets></p></caption><graphic xlink:href="13300_2014_59_Fig3_HTML" id="MO3"></graphic></fig><table-wrap id="Tab2"><label><offsets xml_i="24176" xml_f="24183" txt_i="15678" txt_f="15685">Table 2</offsets></label><caption><p><offsets xml_i="24203" xml_f="24216" txt_i="15685" txt_f="15698">Change in HbA</offsets><sub><offsets xml_i="24221" xml_f="24223" txt_i="15698" txt_f="15700">1c</offsets></sub><offsets xml_i="24229" xml_f="24325" txt_i="15700" txt_f="15796"> (%) in subpopulations of patients taking metformin 250 mg bid or 500 mg bid (full analysis set)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="24404" xml_f="24413" txt_i="15797" txt_f="15806">Treatment</offsets></th><th align="left"><offsets xml_i="24435" xml_f="24436" txt_i="15806" txt_f="15807">
</offsets><italic><offsets xml_i="24444" xml_f="24445" txt_i="15807" txt_f="15808">n</offsets></italic><offsets xml_i="24454" xml_f="24455" txt_i="15808" txt_f="15809">
</offsets></th><th align="left"><offsets xml_i="24477" xml_f="24495" txt_i="15809" txt_f="15827">Baseline mean (SE)</offsets></th><th align="left"><offsets xml_i="24517" xml_f="24533" txt_i="15827" txt_f="15843">Mean change (SE)</offsets></th><th align="left"><offsets xml_i="24555" xml_f="24563" txt_i="15843" txt_f="15851">95% CI (</offsets><italic><offsets xml_i="24571" xml_f="24572" txt_i="15851" txt_f="15852">P</offsets></italic><offsets xml_i="24581" xml_f="24588" txt_i="15852" txt_f="15859"> value)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="24634" xml_f="24669" txt_i="15859" txt_f="15894">Vildagliptin + metformin 250 mg bid</offsets></td><td align="left"><offsets xml_i="24691" xml_f="24693" txt_i="15895" txt_f="15897">34</offsets></td><td char="(" align="char"><offsets xml_i="24724" xml_f="24734" txt_i="15898" txt_f="15908">7.9 (0.13)</offsets></td><td char="(" align="char"><offsets xml_i="24765" xml_f="24776" txt_i="15909" txt_f="15920">−1.1 (0.09)</offsets></td><td char="(" align="char"><offsets xml_i="24807" xml_f="24821" txt_i="15921" txt_f="15935">−1.24, −0.88 (</offsets><italic><offsets xml_i="24829" xml_f="24830" txt_i="15935" txt_f="15936">P</offsets></italic><offsets xml_i="24839" xml_f="24851" txt_i="15936" txt_f="15945"> &lt; 0.001)</offsets></td></tr><tr><td align="left"><offsets xml_i="24882" xml_f="24917" txt_i="15946" txt_f="15981">Vildagliptin + metformin 500 mg bid</offsets></td><td align="left"><offsets xml_i="24939" xml_f="24941" txt_i="15982" txt_f="15984">34</offsets></td><td char="(" align="char"><offsets xml_i="24972" xml_f="24982" txt_i="15985" txt_f="15995">8.1 (0.15)</offsets></td><td char="(" align="char"><offsets xml_i="25013" xml_f="25024" txt_i="15996" txt_f="16007">−1.1 (0.09)</offsets></td><td char="(" align="char"><offsets xml_i="25055" xml_f="25069" txt_i="16008" txt_f="16022">−1.24, −0.88 (</offsets><italic><offsets xml_i="25077" xml_f="25078" txt_i="16022" txt_f="16023">P</offsets></italic><offsets xml_i="25087" xml_f="25099" txt_i="16023" txt_f="16032"> &lt; 0.001)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="25145" xml_f="25146" txt_i="16033" txt_f="16034">
</offsets><italic><offsets xml_i="25154" xml_f="25156" txt_i="16034" txt_f="16036">CI</offsets></italic><offsets xml_i="25165" xml_f="25187" txt_i="16036" txt_f="16058"> confidence interval, </offsets><italic><offsets xml_i="25195" xml_f="25198" txt_i="16058" txt_f="16061">HbA</offsets></italic><offsets xml_i="25207" xml_f="25208" txt_i="16061" txt_f="16062">
</offsets><sub><italic><offsets xml_i="25221" xml_f="25223" txt_i="16062" txt_f="16064">1c</offsets></italic></sub><offsets xml_i="25238" xml_f="25264" txt_i="16064" txt_f="16090"> glycosylated hemoglobin, </offsets><italic><offsets xml_i="25272" xml_f="25274" txt_i="16090" txt_f="16092">SE</offsets></italic><offsets xml_i="25283" xml_f="25298" txt_i="16092" txt_f="16107"> standard error</offsets></p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label><offsets xml_i="25362" xml_f="25369" txt_i="16108" txt_f="16115">Table 3</offsets></label><caption><p><offsets xml_i="25389" xml_f="25392" txt_i="16115" txt_f="16118">HbA</offsets><sub><offsets xml_i="25397" xml_f="25399" txt_i="16118" txt_f="16120">1c</offsets></sub><offsets xml_i="25405" xml_f="25441" txt_i="16120" txt_f="16156"> responder rates (full analysis set)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="25520" xml_f="25538" txt_i="16157" txt_f="16175">Responder criteria</offsets></th><th align="left"><offsets xml_i="25560" xml_f="25585" txt_i="16175" txt_f="16200">Vildagliptin + metformin </offsets><italic><offsets xml_i="25593" xml_f="25594" txt_i="16200" txt_f="16201">n</offsets></italic><offsets xml_i="25603" xml_f="25608" txt_i="16201" txt_f="16206"> = 68</offsets></th><th align="left"><offsets xml_i="25630" xml_f="25650" txt_i="16206" txt_f="16226">Placebo + metformin </offsets><italic><offsets xml_i="25658" xml_f="25659" txt_i="16226" txt_f="16227">n</offsets></italic><offsets xml_i="25668" xml_f="25673" txt_i="16227" txt_f="16232"> = 70</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="25719" xml_f="25722" txt_i="16232" txt_f="16235">HbA</offsets><sub><offsets xml_i="25727" xml_f="25729" txt_i="16235" txt_f="16237">1c</offsets></sub><offsets xml_i="25735" xml_f="25743" txt_i="16237" txt_f="16245"> ≤6.5%, </offsets><italic><offsets xml_i="25751" xml_f="25754" txt_i="16245" txt_f="16248">n/N</offsets></italic><offsets xml_i="25763" xml_f="25764" txt_i="16248" txt_f="16249">
</offsets><sup><offsets xml_i="25769" xml_f="25770" txt_i="16249" txt_f="16250">a</offsets></sup><offsets xml_i="25776" xml_f="25780" txt_i="16250" txt_f="16254"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="25811" xml_f="25824" txt_i="16255" txt_f="16268">21/68 (30.9)*</offsets></td><td char="(" align="char"><offsets xml_i="25855" xml_f="25865" txt_i="16269" txt_f="16279">2/70 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="25896" xml_f="25899" txt_i="16280" txt_f="16283">HbA</offsets><sub><offsets xml_i="25904" xml_f="25906" txt_i="16283" txt_f="16285">1c</offsets></sub><offsets xml_i="25912" xml_f="25923" txt_i="16285" txt_f="16293"> &lt;7.0%, </offsets><italic><offsets xml_i="25931" xml_f="25932" txt_i="16293" txt_f="16294">n</offsets></italic><offsets xml_i="25941" xml_f="25942" txt_i="16294" txt_f="16295">/</offsets><italic><offsets xml_i="25950" xml_f="25951" txt_i="16295" txt_f="16296">N</offsets></italic><offsets xml_i="25960" xml_f="25961" txt_i="16296" txt_f="16297">
</offsets><sup><offsets xml_i="25966" xml_f="25967" txt_i="16297" txt_f="16298">b</offsets></sup><offsets xml_i="25973" xml_f="25977" txt_i="16298" txt_f="16302"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="26008" xml_f="26021" txt_i="16303" txt_f="16316">41/64 (64.1)*</offsets></td><td char="(" align="char"><offsets xml_i="26052" xml_f="26063" txt_i="16317" txt_f="16328">9/59 (15.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="26094" xml_f="26110" txt_i="16329" txt_f="16345">Reduction of HbA</offsets><sub><offsets xml_i="26115" xml_f="26117" txt_i="16345" txt_f="16347">1c</offsets></sub><offsets xml_i="26123" xml_f="26129" txt_i="16347" txt_f="16353"> ≥1%, </offsets><italic><offsets xml_i="26137" xml_f="26138" txt_i="16353" txt_f="16354">n</offsets></italic><offsets xml_i="26147" xml_f="26148" txt_i="16354" txt_f="16355">/</offsets><italic><offsets xml_i="26156" xml_f="26157" txt_i="16355" txt_f="16356">N</offsets></italic><offsets xml_i="26166" xml_f="26167" txt_i="16356" txt_f="16357">
</offsets><sup><offsets xml_i="26172" xml_f="26173" txt_i="16357" txt_f="16358">c</offsets></sup><offsets xml_i="26179" xml_f="26183" txt_i="16358" txt_f="16362"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="26214" xml_f="26227" txt_i="16363" txt_f="16376">39/68 (57.4)*</offsets></td><td char="(" align="char"><offsets xml_i="26258" xml_f="26268" txt_i="16377" txt_f="16387">3/70 (4.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="26299" xml_f="26315" txt_i="16388" txt_f="16404">Reduction of HbA</offsets><sub><offsets xml_i="26320" xml_f="26322" txt_i="16404" txt_f="16406">1c</offsets></sub><offsets xml_i="26328" xml_f="26336" txt_i="16406" txt_f="16414"> ≥0.5%, </offsets><italic><offsets xml_i="26344" xml_f="26345" txt_i="16414" txt_f="16415">n</offsets></italic><offsets xml_i="26354" xml_f="26355" txt_i="16415" txt_f="16416">/</offsets><italic><offsets xml_i="26363" xml_f="26364" txt_i="16416" txt_f="16417">N</offsets></italic><offsets xml_i="26373" xml_f="26374" txt_i="16417" txt_f="16418">
</offsets><sup><offsets xml_i="26379" xml_f="26380" txt_i="16418" txt_f="16419">c</offsets></sup><offsets xml_i="26386" xml_f="26390" txt_i="16419" txt_f="16423"> (%)</offsets></td><td char="(" align="char"><offsets xml_i="26421" xml_f="26434" txt_i="16424" txt_f="16437">59/68 (86.8)*</offsets></td><td char="(" align="char"><offsets xml_i="26465" xml_f="26477" txt_i="16438" txt_f="16450">13/70 (18.6)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="26523" xml_f="26524" txt_i="16451" txt_f="16452">
</offsets><italic><offsets xml_i="26532" xml_f="26535" txt_i="16452" txt_f="16455">HbA</offsets></italic><offsets xml_i="26544" xml_f="26545" txt_i="16455" txt_f="16456">
</offsets><sub><italic><offsets xml_i="26558" xml_f="26560" txt_i="16456" txt_f="16458">1c</offsets></italic></sub><offsets xml_i="26575" xml_f="26599" txt_i="16458" txt_f="16482"> glycosylated hemoglobin</offsets></p><p><offsets xml_i="26606" xml_f="26608" txt_i="16483" txt_f="16485">* </offsets><italic><offsets xml_i="26616" xml_f="26617" txt_i="16485" txt_f="16486">P</offsets></italic><offsets xml_i="26626" xml_f="26637" txt_i="16486" txt_f="16494"> &lt; 0.001</offsets></p><p><offsets xml_i="26644" xml_f="26645" txt_i="16495" txt_f="16496">
</offsets><sup><offsets xml_i="26650" xml_f="26651" txt_i="16496" txt_f="16497">a</offsets></sup><offsets xml_i="26657" xml_f="26709" txt_i="16497" txt_f="16549">Denominator includes patients with a baseline of HbA</offsets><sub><offsets xml_i="26714" xml_f="26716" txt_i="16549" txt_f="16551">1c</offsets></sub><offsets xml_i="26722" xml_f="26748" txt_i="16551" txt_f="16574"> &gt;6.5% and endpoint HbA</offsets><sub><offsets xml_i="26753" xml_f="26755" txt_i="16574" txt_f="16576">1c</offsets></sub><offsets xml_i="26761" xml_f="26773" txt_i="16576" txt_f="16588"> measurement</offsets></p><p><offsets xml_i="26780" xml_f="26781" txt_i="16589" txt_f="16590">
</offsets><sup><offsets xml_i="26786" xml_f="26787" txt_i="16590" txt_f="16591">b</offsets></sup><offsets xml_i="26793" xml_f="26845" txt_i="16591" txt_f="16643">Denominator includes patients with a baseline of HbA</offsets><sub><offsets xml_i="26850" xml_f="26852" txt_i="16643" txt_f="16645">1c</offsets></sub><offsets xml_i="26858" xml_f="26879" txt_i="16645" txt_f="16666"> ≥7% and endpoint HbA</offsets><sub><offsets xml_i="26884" xml_f="26886" txt_i="16666" txt_f="16668">1c</offsets></sub><offsets xml_i="26892" xml_f="26904" txt_i="16668" txt_f="16680"> measurement</offsets></p><p><offsets xml_i="26911" xml_f="26912" txt_i="16681" txt_f="16682">
</offsets><sup><offsets xml_i="26917" xml_f="26918" txt_i="16682" txt_f="16683">c</offsets></sup><offsets xml_i="26924" xml_f="26989" txt_i="16683" txt_f="16748">Denominator includes patients with both baseline and endpoint HbA</offsets><sub><offsets xml_i="26994" xml_f="26996" txt_i="16748" txt_f="16750">1c</offsets></sub><offsets xml_i="27002" xml_f="27015" txt_i="16750" txt_f="16763"> measurements</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="27057" xml_f="27080" txt_i="16765" txt_f="16788">The mean changes in HbA</offsets><sub><offsets xml_i="27085" xml_f="27087" txt_i="16788" txt_f="16790">1c</offsets></sub><offsets xml_i="27093" xml_f="27191" txt_i="16790" txt_f="16888"> from baseline to endpoint in the subgroups of patients by age, gender, baseline BMI, baseline HbA</offsets><sub><offsets xml_i="27196" xml_f="27198" txt_i="16888" txt_f="16890">1c</offsets></sub><offsets xml_i="27204" xml_f="27245" txt_i="16890" txt_f="16931"> and baseline FPG are presented in Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="27279" xml_f="27280" txt_i="16931" txt_f="16932">4</offsets></xref><offsets xml_i="27287" xml_f="27312" txt_i="16932" txt_f="16957">. The mean changes in HbA</offsets><sub><offsets xml_i="27317" xml_f="27319" txt_i="16957" txt_f="16959">1c</offsets></sub><offsets xml_i="27325" xml_f="27426" txt_i="16959" txt_f="17060"> were greater for vildagliptin compared with placebo across all the subgroups. Mean reductions in HbA</offsets><sub><offsets xml_i="27431" xml_f="27433" txt_i="17060" txt_f="17062">1c</offsets></sub><offsets xml_i="27439" xml_f="27531" txt_i="17062" txt_f="17154"> in the vildagliptin group were higher in the subgroups of patients with higher baseline HbA</offsets><sub><offsets xml_i="27536" xml_f="27538" txt_i="17154" txt_f="17156">1c</offsets></sub><offsets xml_i="27544" xml_f="27549" txt_i="17156" txt_f="17161"> (HbA</offsets><sub><offsets xml_i="27554" xml_f="27556" txt_i="17161" txt_f="17163">1c</offsets></sub><offsets xml_i="27562" xml_f="27658" txt_i="17163" txt_f="17250"> &gt;8% to ≤9% or &gt;9%) or FPG (≥8.9 mmol/L) and in those with lower baseline BMI (&lt;25 kg/m</offsets><sup><offsets xml_i="27663" xml_f="27664" txt_i="17250" txt_f="17251">2</offsets></sup><offsets xml_i="27670" xml_f="27672" txt_i="17251" txt_f="17253">).</offsets><table-wrap id="Tab4"><label><offsets xml_i="27701" xml_f="27708" txt_i="17253" txt_f="17260">Table 4</offsets></label><caption><p><offsets xml_i="27728" xml_f="27747" txt_i="17260" txt_f="17279">Mean changes in HbA</offsets><sub><offsets xml_i="27752" xml_f="27754" txt_i="17279" txt_f="17281">1c</offsets></sub><offsets xml_i="27760" xml_f="27823" txt_i="17281" txt_f="17344"> (%) from baseline to endpoint by subgroups (full analysis set)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"><offsets xml_i="27914" xml_f="27923" txt_i="17345" txt_f="17354">Subgroups</offsets></th><th align="left" colspan="3"><offsets xml_i="27957" xml_f="27982" txt_i="17354" txt_f="17379">Vildagliptin + metformin </offsets><italic><offsets xml_i="27990" xml_f="27991" txt_i="17379" txt_f="17380">n</offsets></italic><offsets xml_i="28000" xml_f="28005" txt_i="17380" txt_f="17385"> = 68</offsets></th><th align="left" colspan="3"><offsets xml_i="28039" xml_f="28059" txt_i="17385" txt_f="17405">Placebo + metformin </offsets><italic><offsets xml_i="28067" xml_f="28068" txt_i="17405" txt_f="17406">n</offsets></italic><offsets xml_i="28077" xml_f="28082" txt_i="17406" txt_f="17411"> = 70</offsets></th></tr><tr><th align="left"><offsets xml_i="28113" xml_f="28114" txt_i="17411" txt_f="17412">
</offsets><italic><offsets xml_i="28122" xml_f="28123" txt_i="17412" txt_f="17413">n</offsets></italic><offsets xml_i="28132" xml_f="28133" txt_i="17413" txt_f="17414">
</offsets></th><th align="left"><offsets xml_i="28155" xml_f="28156" txt_i="17414" txt_f="17415">
</offsets><italic><offsets xml_i="28164" xml_f="28166" txt_i="17415" txt_f="17417">BL</offsets></italic><offsets xml_i="28175" xml_f="28180" txt_i="17417" txt_f="17422"> mean</offsets></th><th align="left"><offsets xml_i="28202" xml_f="28213" txt_i="17422" txt_f="17433">Change (SE)</offsets></th><th align="left"><offsets xml_i="28235" xml_f="28236" txt_i="17433" txt_f="17434">
</offsets><italic><offsets xml_i="28244" xml_f="28245" txt_i="17434" txt_f="17435">N</offsets></italic><offsets xml_i="28254" xml_f="28255" txt_i="17435" txt_f="17436">
</offsets></th><th align="left"><offsets xml_i="28277" xml_f="28278" txt_i="17436" txt_f="17437">
</offsets><italic><offsets xml_i="28286" xml_f="28288" txt_i="17437" txt_f="17439">BL</offsets></italic><offsets xml_i="28297" xml_f="28302" txt_i="17439" txt_f="17444"> mean</offsets></th><th align="left"><offsets xml_i="28324" xml_f="28335" txt_i="17444" txt_f="17455">Change (SE)</offsets></th></tr></thead><tbody><tr><td align="left" colspan="7"><offsets xml_i="28393" xml_f="28404" txt_i="17455" txt_f="17466">Age (years)</offsets></td></tr><tr><td align="left"><offsets xml_i="28435" xml_f="28442" txt_i="17467" txt_f="17471"> &lt;65</offsets></td><td align="left"><offsets xml_i="28464" xml_f="28466" txt_i="17472" txt_f="17474">47</offsets></td><td align="left"><offsets xml_i="28488" xml_f="28491" txt_i="17475" txt_f="17478">7.9</offsets></td><td char="(" align="char"><offsets xml_i="28522" xml_f="28533" txt_i="17479" txt_f="17490">−1.1 (0.08)</offsets></td><td align="left"><offsets xml_i="28555" xml_f="28557" txt_i="17491" txt_f="17493">54</offsets></td><td align="left"><offsets xml_i="28579" xml_f="28582" txt_i="17494" txt_f="17497">8.0</offsets></td><td char="(" align="char"><offsets xml_i="28613" xml_f="28624" txt_i="17498" txt_f="17509">−0.1 (0.08)</offsets></td></tr><tr><td align="left"><offsets xml_i="28655" xml_f="28659" txt_i="17510" txt_f="17514"> ≥65</offsets></td><td align="left"><offsets xml_i="28681" xml_f="28683" txt_i="17515" txt_f="17517">21</offsets></td><td align="left"><offsets xml_i="28705" xml_f="28708" txt_i="17518" txt_f="17521">8.3</offsets></td><td char="(" align="char"><offsets xml_i="28739" xml_f="28750" txt_i="17522" txt_f="17533">−1.1 (0.15)</offsets></td><td align="left"><offsets xml_i="28772" xml_f="28774" txt_i="17534" txt_f="17536">16</offsets></td><td align="left"><offsets xml_i="28796" xml_f="28799" txt_i="17537" txt_f="17540">7.9</offsets></td><td char="(" align="char"><offsets xml_i="28830" xml_f="28841" txt_i="17541" txt_f="17552">−0.2 (0.08)</offsets></td></tr><tr><td align="left" colspan="7"><offsets xml_i="28884" xml_f="28890" txt_i="17553" txt_f="17559">Gender</offsets></td></tr><tr><td align="left"><offsets xml_i="28921" xml_f="28926" txt_i="17560" txt_f="17565"> Male</offsets></td><td align="left"><offsets xml_i="28948" xml_f="28950" txt_i="17566" txt_f="17568">44</offsets></td><td align="left"><offsets xml_i="28972" xml_f="28975" txt_i="17569" txt_f="17572">7.9</offsets></td><td char="(" align="char"><offsets xml_i="29006" xml_f="29017" txt_i="17573" txt_f="17584">−1.0 (0.10)</offsets></td><td align="left"><offsets xml_i="29039" xml_f="29041" txt_i="17585" txt_f="17587">48</offsets></td><td align="left"><offsets xml_i="29063" xml_f="29066" txt_i="17588" txt_f="17591">8.1</offsets></td><td char="(" align="char"><offsets xml_i="29097" xml_f="29108" txt_i="17592" txt_f="17603">−0.2 (0.07)</offsets></td></tr><tr><td align="left"><offsets xml_i="29139" xml_f="29146" txt_i="17604" txt_f="17611"> Female</offsets></td><td align="left"><offsets xml_i="29168" xml_f="29170" txt_i="17612" txt_f="17614">24</offsets></td><td align="left"><offsets xml_i="29192" xml_f="29195" txt_i="17615" txt_f="17618">8.2</offsets></td><td char="(" align="char"><offsets xml_i="29226" xml_f="29237" txt_i="17619" txt_f="17630">−1.2 (0.09)</offsets></td><td align="left"><offsets xml_i="29259" xml_f="29261" txt_i="17631" txt_f="17633">22</offsets></td><td align="left"><offsets xml_i="29283" xml_f="29286" txt_i="17634" txt_f="17637">7.9</offsets></td><td char="(" align="char"><offsets xml_i="29317" xml_f="29328" txt_i="17638" txt_f="17649">−0.1 (0.13)</offsets></td></tr><tr><td align="left" colspan="7"><offsets xml_i="29371" xml_f="29380" txt_i="17650" txt_f="17659">BMI (kg/m</offsets><sup><offsets xml_i="29385" xml_f="29386" txt_i="17659" txt_f="17660">2</offsets></sup><offsets xml_i="29392" xml_f="29393" txt_i="17660" txt_f="17661">)</offsets></td></tr><tr><td align="left"><offsets xml_i="29424" xml_f="29431" txt_i="17662" txt_f="17666"> &lt;25</offsets></td><td align="left"><offsets xml_i="29453" xml_f="29455" txt_i="17667" txt_f="17669">32</offsets></td><td align="left"><offsets xml_i="29477" xml_f="29480" txt_i="17670" txt_f="17673">8.0</offsets></td><td char="(" align="char"><offsets xml_i="29511" xml_f="29522" txt_i="17674" txt_f="17685">−1.2 (0.11)</offsets></td><td align="left"><offsets xml_i="29544" xml_f="29546" txt_i="17686" txt_f="17688">35</offsets></td><td align="left"><offsets xml_i="29568" xml_f="29571" txt_i="17689" txt_f="17692">7.8</offsets></td><td char="(" align="char"><offsets xml_i="29602" xml_f="29613" txt_i="17693" txt_f="17704">−0.2 (0.08)</offsets></td></tr><tr><td align="left"><offsets xml_i="29644" xml_f="29648" txt_i="17705" txt_f="17709"> ≥25</offsets></td><td align="left"><offsets xml_i="29670" xml_f="29672" txt_i="17710" txt_f="17712">36</offsets></td><td align="left"><offsets xml_i="29694" xml_f="29697" txt_i="17713" txt_f="17716">8.0</offsets></td><td char="(" align="char"><offsets xml_i="29728" xml_f="29739" txt_i="17717" txt_f="17728">−0.9 (0.08)</offsets></td><td align="left"><offsets xml_i="29761" xml_f="29763" txt_i="17729" txt_f="17731">35</offsets></td><td align="left"><offsets xml_i="29785" xml_f="29788" txt_i="17732" txt_f="17735">8.2</offsets></td><td char="(" align="char"><offsets xml_i="29819" xml_f="29829" txt_i="17736" txt_f="17746">0.0 (0.10)</offsets></td></tr><tr><td align="left" colspan="7"><offsets xml_i="29872" xml_f="29875" txt_i="17747" txt_f="17750">HbA</offsets><sub><offsets xml_i="29880" xml_f="29882" txt_i="17750" txt_f="17752">1c</offsets></sub><offsets xml_i="29888" xml_f="29892" txt_i="17752" txt_f="17756"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29923" xml_f="29926" txt_i="17757" txt_f="17760"> ≤8</offsets></td><td align="left"><offsets xml_i="29948" xml_f="29950" txt_i="17761" txt_f="17763">40</offsets></td><td align="left"><offsets xml_i="29972" xml_f="29975" txt_i="17764" txt_f="17767">7.4</offsets></td><td char="(" align="char"><offsets xml_i="30006" xml_f="30017" txt_i="17768" txt_f="17779">−0.9 (0.07)</offsets></td><td align="left"><offsets xml_i="30039" xml_f="30041" txt_i="17780" txt_f="17782">40</offsets></td><td align="left"><offsets xml_i="30063" xml_f="30066" txt_i="17783" txt_f="17786">7.3</offsets></td><td char="(" align="char"><offsets xml_i="30097" xml_f="30107" txt_i="17787" txt_f="17797">0.0 (0.08)</offsets></td></tr><tr><td align="left"><offsets xml_i="30138" xml_f="30150" txt_i="17798" txt_f="17807"> &gt;8 to ≤9</offsets></td><td align="left"><offsets xml_i="30172" xml_f="30174" txt_i="17808" txt_f="17810">17</offsets></td><td align="left"><offsets xml_i="30196" xml_f="30199" txt_i="17811" txt_f="17814">8.3</offsets></td><td char="(" align="char"><offsets xml_i="30230" xml_f="30241" txt_i="17815" txt_f="17826">−1.1 (0.14)</offsets></td><td align="left"><offsets xml_i="30263" xml_f="30265" txt_i="17827" txt_f="17829">14</offsets></td><td align="left"><offsets xml_i="30287" xml_f="30290" txt_i="17830" txt_f="17833">8.5</offsets></td><td char="(" align="char"><offsets xml_i="30321" xml_f="30331" txt_i="17834" txt_f="17844">0.0 (0.10)</offsets></td></tr><tr><td align="left"><offsets xml_i="30362" xml_f="30368" txt_i="17845" txt_f="17848"> &gt;9</offsets></td><td align="left"><offsets xml_i="30390" xml_f="30392" txt_i="17849" txt_f="17851">11</offsets></td><td align="left"><offsets xml_i="30414" xml_f="30417" txt_i="17852" txt_f="17855">9.5</offsets></td><td char="(" align="char"><offsets xml_i="30448" xml_f="30459" txt_i="17856" txt_f="17867">−1.6 (0.26)</offsets></td><td align="left"><offsets xml_i="30481" xml_f="30483" txt_i="17868" txt_f="17870">16</offsets></td><td align="left"><offsets xml_i="30505" xml_f="30508" txt_i="17871" txt_f="17874">9.4</offsets></td><td char="(" align="char"><offsets xml_i="30539" xml_f="30540" txt_i="17875" txt_f="17876">−</offsets></td></tr><tr><td align="left" colspan="7"><offsets xml_i="30583" xml_f="30595" txt_i="17877" txt_f="17889">FPG (mmol/L)</offsets></td></tr><tr><td align="left"><offsets xml_i="30626" xml_f="30634" txt_i="17890" txt_f="17895"> &lt;8.9</offsets></td><td align="left"><offsets xml_i="30656" xml_f="30658" txt_i="17896" txt_f="17898">41</offsets></td><td align="left"><offsets xml_i="30680" xml_f="30683" txt_i="17899" txt_f="17902">7.6</offsets></td><td char="(" align="char"><offsets xml_i="30714" xml_f="30725" txt_i="17903" txt_f="17914">−1.0 (0.08)</offsets></td><td align="left"><offsets xml_i="30747" xml_f="30749" txt_i="17915" txt_f="17917">34</offsets></td><td align="left"><offsets xml_i="30771" xml_f="30774" txt_i="17918" txt_f="17921">7.3</offsets></td><td char="(" align="char"><offsets xml_i="30805" xml_f="30816" txt_i="17922" txt_f="17933">−0.1 (0.06)</offsets></td></tr><tr><td align="left"><offsets xml_i="30847" xml_f="30852" txt_i="17934" txt_f="17939"> ≥8.9</offsets></td><td align="left"><offsets xml_i="30874" xml_f="30876" txt_i="17940" txt_f="17942">27</offsets></td><td align="left"><offsets xml_i="30898" xml_f="30901" txt_i="17943" txt_f="17946">8.6</offsets></td><td char="(" align="char"><offsets xml_i="30932" xml_f="30943" txt_i="17947" txt_f="17958">−1.2 (0.14)</offsets></td><td align="left"><offsets xml_i="30965" xml_f="30967" txt_i="17959" txt_f="17961">36</offsets></td><td align="left"><offsets xml_i="30989" xml_f="30992" txt_i="17962" txt_f="17965">8.7</offsets></td><td char="(" align="char"><offsets xml_i="31023" xml_f="31034" txt_i="17966" txt_f="17977">−0.1 (0.11)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="31080" xml_f="31081" txt_i="17978" txt_f="17979">
</offsets><italic><offsets xml_i="31089" xml_f="31091" txt_i="17979" txt_f="17981">BL</offsets></italic><offsets xml_i="31100" xml_f="31111" txt_i="17981" txt_f="17992"> baseline, </offsets><italic><offsets xml_i="31119" xml_f="31122" txt_i="17992" txt_f="17995">BMI</offsets></italic><offsets xml_i="31131" xml_f="31149" txt_i="17995" txt_f="18013"> body mass index, </offsets><italic><offsets xml_i="31157" xml_f="31160" txt_i="18013" txt_f="18016">FPG</offsets></italic><offsets xml_i="31169" xml_f="31194" txt_i="18016" txt_f="18041"> fasting plasma glucose, </offsets><italic><offsets xml_i="31202" xml_f="31205" txt_i="18041" txt_f="18044">HbA</offsets></italic><offsets xml_i="31214" xml_f="31215" txt_i="18044" txt_f="18045">
</offsets><sub><italic><offsets xml_i="31228" xml_f="31230" txt_i="18045" txt_f="18047">1c</offsets></italic></sub><offsets xml_i="31245" xml_f="31271" txt_i="18047" txt_f="18073"> glycosylated hemoglobin, </offsets><italic><offsets xml_i="31279" xml_f="31281" txt_i="18073" txt_f="18075">SE</offsets></italic><offsets xml_i="31290" xml_f="31305" txt_i="18075" txt_f="18090"> standard error</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="31347" xml_f="31446" txt_i="18092" txt_f="18191">Vildagliptin showed sustained reduction in FPG over placebo during the 12 weeks of treatment (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="31478" xml_f="31479" txt_i="18191" txt_f="18192">4</offsets></xref><offsets xml_i="31486" xml_f="31723" txt_i="18192" txt_f="18429">a). The AM∆ ± SE in FPG from baseline to endpoint was greater in patients receiving vildagliptin (−1.7 ± 0.16 mmol/L) compared with those receiving placebo (−0.1 ± 0.16 mmol/L), with a between-treatment difference of −1.6 ± 0.22 mmol/L (</offsets><italic><offsets xml_i="31731" xml_f="31732" txt_i="18429" txt_f="18430">P</offsets></italic><offsets xml_i="31741" xml_f="31760" txt_i="18430" txt_f="18446"> &lt; 0.001) (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="31792" xml_f="31793" txt_i="18446" txt_f="18447">4</offsets></xref><offsets xml_i="31800" xml_f="31803" txt_i="18447" txt_f="18450">b).</offsets><fig id="Fig4"><label><offsets xml_i="31825" xml_f="31831" txt_i="18450" txt_f="18456">Fig. 4</offsets></label><caption><p><offsets xml_i="31851" xml_f="31852" txt_i="18456" txt_f="18457">
</offsets><bold><offsets xml_i="31858" xml_f="31859" txt_i="18457" txt_f="18458">a</offsets></bold><offsets xml_i="31866" xml_f="31940" txt_i="18458" txt_f="18532"> Fasting plasma glucose (FPG) by treatment and visit (full analysis set). </offsets><bold><offsets xml_i="31946" xml_f="31947" txt_i="18532" txt_f="18533">b</offsets></bold><offsets xml_i="31954" xml_f="32030" txt_i="18533" txt_f="18609"> Adjusted mean change in FPG from baseline to endpoint (full analysis set). </offsets><italic><offsets xml_i="32038" xml_f="32040" txt_i="18609" txt_f="18611">BL</offsets></italic><offsets xml_i="32049" xml_f="32060" txt_i="18611" txt_f="18622"> baseline, </offsets><italic><offsets xml_i="32068" xml_f="32070" txt_i="18622" txt_f="18624">EP</offsets></italic><offsets xml_i="32079" xml_f="32090" txt_i="18624" txt_f="18635"> endpoint, </offsets><italic><offsets xml_i="32098" xml_f="32100" txt_i="18635" txt_f="18637">SE</offsets></italic><offsets xml_i="32109" xml_f="32127" txt_i="18637" txt_f="18655"> standard error. *</offsets><italic><offsets xml_i="32135" xml_f="32136" txt_i="18655" txt_f="18656">P</offsets></italic><offsets xml_i="32145" xml_f="32156" txt_i="18656" txt_f="18664"> &lt; 0.001</offsets></p></caption><graphic xlink:href="13300_2014_59_Fig4_HTML" id="MO4"></graphic></fig></p></sec><sec id="Sec11"><title><offsets xml_i="32274" xml_f="32280" txt_i="18667" txt_f="18673">Safety</offsets></title><p><offsets xml_i="32291" xml_f="32677" txt_i="18674" txt_f="19060">The overall proportion of patients experiencing AEs was comparable between the vildagliptin (44.1%) and placebo (41.4%) groups. The most commonly reported AE by primary SOC was “infections and infestations” (13.2% for vildagliptin and 14.3% for placebo). The most frequently reported AE (≥2% in any group) by PT was “nasopharyngitis” (7.4% for vildagliptin and 5.7% for placebo) (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="32711" xml_f="32712" txt_i="19060" txt_f="19061">5</offsets></xref><offsets xml_i="32719" xml_f="33971" txt_i="19061" txt_f="20313">). While incidence of AEs was low across PTs in both the treatment groups, “amylase increased” was reported in more patients with vildagliptin (4 patients; 5.9%) than with placebo (1 patient; 1.4%) and anemia was more frequent with placebo (3 patients; 4.3%) than with vildagliptin (0 patient). All the events of increased amylase levels were classified as mild and clinically asymptomatic. All the reported AEs were mild or moderate in severity. The incidence of AEs suspected to be related to the study drug was slightly higher in the vildagliptin group than in the placebo group (16.2% vs. 10.0%). One patient in the vildagliptin group and two patients in the placebo group discontinued the study. No SAEs were reported in the vildagliptin group, whereas one SAE of myocardial infarction was reported in the placebo group. There were no deaths during the study. No hypoglycemic events were reported in the study. There was no change in body weight from baseline to endpoint for both treatment groups (+0.3 kg for vildagliptin and −0.2 kg for placebo). There were no clinically relevant changes or trends in the hematological, biochemical (including lipid parameters), hepatic enzyme, urinalysis parameters, and vital signs in either treatment group.</offsets><table-wrap id="Tab5"><label><offsets xml_i="34000" xml_f="34007" txt_i="20313" txt_f="20320">Table 5</offsets></label><caption><p><offsets xml_i="34027" xml_f="34131" txt_i="20320" txt_f="20424">Number (%) of patients reporting common adverse events (≥2% in any group) by preferred term (safety set)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="34210" xml_f="34226" txt_i="20425" txt_f="20441">Preferred term, </offsets><italic><offsets xml_i="34234" xml_f="34235" txt_i="20441" txt_f="20442">n</offsets></italic><offsets xml_i="34244" xml_f="34248" txt_i="20442" txt_f="20446"> (%)</offsets></th><th align="left"><offsets xml_i="34270" xml_f="34295" txt_i="20446" txt_f="20471">Vildagliptin + metformin </offsets><italic><offsets xml_i="34303" xml_f="34304" txt_i="20471" txt_f="20472">n</offsets></italic><offsets xml_i="34313" xml_f="34318" txt_i="20472" txt_f="20477"> = 68</offsets></th><th align="left"><offsets xml_i="34340" xml_f="34360" txt_i="20477" txt_f="20497">Placebo + metformin </offsets><italic><offsets xml_i="34368" xml_f="34369" txt_i="20497" txt_f="20498">n</offsets></italic><offsets xml_i="34378" xml_f="34383" txt_i="20498" txt_f="20503"> = 70</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="34429" xml_f="34447" txt_i="20503" txt_f="20521">Any preferred term</offsets></td><td char="(" align="char"><offsets xml_i="34478" xml_f="34487" txt_i="20522" txt_f="20531">30 (44.1)</offsets></td><td char="(" align="char"><offsets xml_i="34518" xml_f="34527" txt_i="20532" txt_f="20541">29 (41.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="34558" xml_f="34574" txt_i="20542" txt_f="20558"> Nasopharyngitis</offsets></td><td char="(" align="char"><offsets xml_i="34605" xml_f="34612" txt_i="20559" txt_f="20566">5 (7.4)</offsets></td><td char="(" align="char"><offsets xml_i="34643" xml_f="34650" txt_i="20567" txt_f="20574">4 (5.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="34681" xml_f="34699" txt_i="20575" txt_f="20593"> Amylase increased</offsets></td><td char="(" align="char"><offsets xml_i="34730" xml_f="34737" txt_i="20594" txt_f="20601">4 (5.9)</offsets></td><td char="(" align="char"><offsets xml_i="34768" xml_f="34775" txt_i="20602" txt_f="20609">1 (1.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="34806" xml_f="34820" txt_i="20610" txt_f="20624"> Dental caries</offsets></td><td char="(" align="char"><offsets xml_i="34851" xml_f="34858" txt_i="20625" txt_f="20632">2 (2.9)</offsets></td><td char="(" align="char"><offsets xml_i="34889" xml_f="34896" txt_i="20633" txt_f="20640">0 (0.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="34927" xml_f="34945" txt_i="20641" txt_f="20659"> Gastritis erosive</offsets></td><td char="(" align="char"><offsets xml_i="34976" xml_f="34983" txt_i="20660" txt_f="20667">2 (2.9)</offsets></td><td char="(" align="char"><offsets xml_i="35014" xml_f="35021" txt_i="20668" txt_f="20675">0 (0.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="35052" xml_f="35068" txt_i="20676" txt_f="20692"> Tinea infection</offsets></td><td char="(" align="char"><offsets xml_i="35099" xml_f="35106" txt_i="20693" txt_f="20700">2 (2.9)</offsets></td><td char="(" align="char"><offsets xml_i="35137" xml_f="35144" txt_i="20701" txt_f="20708">0 (0.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="35175" xml_f="35192" txt_i="20709" txt_f="20726"> Lipase increased</offsets></td><td char="(" align="char"><offsets xml_i="35223" xml_f="35230" txt_i="20727" txt_f="20734">2 (2.9)</offsets></td><td char="(" align="char"><offsets xml_i="35261" xml_f="35268" txt_i="20735" txt_f="20742">1 (1.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="35299" xml_f="35312" txt_i="20743" txt_f="20756"> Hypoesthesia</offsets></td><td char="(" align="char"><offsets xml_i="35343" xml_f="35350" txt_i="20757" txt_f="20764">2 (2.9)</offsets></td><td char="(" align="char"><offsets xml_i="35381" xml_f="35388" txt_i="20765" txt_f="20772">0 (0.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="35419" xml_f="35426" txt_i="20773" txt_f="20780"> Anemia</offsets></td><td char="(" align="char"><offsets xml_i="35457" xml_f="35464" txt_i="20781" txt_f="20788">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="35495" xml_f="35502" txt_i="20789" txt_f="20796">3 (4.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="35533" xml_f="35542" txt_i="20797" txt_f="20806"> Diarrhea</offsets></td><td char="(" align="char"><offsets xml_i="35573" xml_f="35580" txt_i="20807" txt_f="20814">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="35611" xml_f="35618" txt_i="20815" txt_f="20822">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="35649" xml_f="35665" txt_i="20823" txt_f="20839"> Gastroenteritis</offsets></td><td char="(" align="char"><offsets xml_i="35696" xml_f="35703" txt_i="20840" txt_f="20847">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="35734" xml_f="35741" txt_i="20848" txt_f="20855">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="35772" xml_f="35807" txt_i="20856" txt_f="20891"> Alanine aminotransferase increased</offsets></td><td char="(" align="char"><offsets xml_i="35838" xml_f="35845" txt_i="20892" txt_f="20899">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="35876" xml_f="35883" txt_i="20900" txt_f="20907">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="35914" xml_f="35951" txt_i="20908" txt_f="20945"> Aspartate aminotransferase increased</offsets></td><td char="(" align="char"><offsets xml_i="35982" xml_f="35989" txt_i="20946" txt_f="20953">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="36020" xml_f="36027" txt_i="20954" txt_f="20961">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="36058" xml_f="36068" txt_i="20962" txt_f="20972"> Back pain</offsets></td><td char="(" align="char"><offsets xml_i="36099" xml_f="36106" txt_i="20973" txt_f="20980">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="36137" xml_f="36144" txt_i="20981" txt_f="20988">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="36175" xml_f="36184" txt_i="20989" txt_f="20998"> Headache</offsets></td><td char="(" align="char"><offsets xml_i="36215" xml_f="36222" txt_i="20999" txt_f="21006">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="36253" xml_f="36260" txt_i="21007" txt_f="21014">2 (2.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="36291" xml_f="36308" txt_i="21015" txt_f="21032"> Tension headache</offsets></td><td char="(" align="char"><offsets xml_i="36339" xml_f="36346" txt_i="21033" txt_f="21040">0 (0.0)</offsets></td><td char="(" align="char"><offsets xml_i="36377" xml_f="36384" txt_i="21041" txt_f="21048">2 (2.9)</offsets></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec12" sec-type="discussion"><title><offsets xml_i="36484" xml_f="36494" txt_i="21052" txt_f="21062">Discussion</offsets></title><p><offsets xml_i="36505" xml_f="36780" txt_i="21063" txt_f="21338">This 12-week, randomized, double-blind study evaluated the efficacy and safety of vildagliptin 50 mg bid in Japanese patients with T2DM inadequately controlled on metformin monotherapy. Vildagliptin produced a statistically significant and clinically meaningful change in HbA</offsets><sub><offsets xml_i="36785" xml_f="36787" txt_i="21338" txt_f="21340">1c</offsets></sub><offsets xml_i="36793" xml_f="36834" txt_i="21340" txt_f="21381"> compared with placebo (−1.1% vs. −0.1%; </offsets><italic><offsets xml_i="36842" xml_f="36843" txt_i="21381" txt_f="21382">P</offsets></italic><offsets xml_i="36852" xml_f="37010" txt_i="21382" txt_f="21537"> &lt; 0.001) as add-on to metformin (250 mg bid or 500 mg bid) after 12 weeks of treatment in Japanese patients with T2DM. Despite the lower baseline mean HbA</offsets><sub><offsets xml_i="37015" xml_f="37017" txt_i="21537" txt_f="21539">1c</offsets></sub><offsets xml_i="37023" xml_f="37267" txt_i="21539" txt_f="21783"> and daily dose of metformin in this study, the between-treatment difference (−1.0%) seen was consistent with the findings previously reported in a predominantly Caucasian population, where vildagliptin-treated patients showed a decrease in HbA</offsets><sub><offsets xml_i="37272" xml_f="37274" txt_i="21783" txt_f="21785">1c</offsets></sub><offsets xml_i="37280" xml_f="37329" txt_i="21785" txt_f="21834"> of 1.1% vs. placebo over 24 weeks of treatment [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="37362" xml_f="37364" txt_i="21834" txt_f="21836">11</offsets></xref><offsets xml_i="37371" xml_f="37404" txt_i="21836" txt_f="21869">]. Moreover, the reduction in HbA</offsets><sub><offsets xml_i="37409" xml_f="37411" txt_i="21869" txt_f="21871">1c</offsets></sub><offsets xml_i="37417" xml_f="37556" txt_i="21871" txt_f="22010"> levels reported with vildagliptin therapy was consistent with other DPP-4 inhibitors with different study designs in Japanese population [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="37589" xml_f="37591" txt_i="22010" txt_f="22012">18</offsets></xref><offsets xml_i="37598" xml_f="37599" txt_i="22012" txt_f="22013">–</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="37632" xml_f="37634" txt_i="22013" txt_f="22015">20</offsets></xref><offsets xml_i="37641" xml_f="37766" txt_i="22015" txt_f="22140">]. These findings indicate that vildagliptin is effective in Japanese patients with T2DM when added to metformin monotherapy.</offsets></p><p><offsets xml_i="37773" xml_f="37870" txt_i="22141" txt_f="22238">Further, vildagliptin showed statistically significant and clinically meaningful reduction in HbA</offsets><sub><offsets xml_i="37875" xml_f="37877" txt_i="22238" txt_f="22240">1c</offsets></sub><offsets xml_i="37883" xml_f="38052" txt_i="22240" txt_f="22409"> after 12 weeks of treatment in the subpopulation of patients receiving metformin 250 mg bid or 500 mg bid. Treatment with vildagliptin produced greater reduction in HbA</offsets><sub><offsets xml_i="38057" xml_f="38059" txt_i="22409" txt_f="22411">1c</offsets></sub><offsets xml_i="38065" xml_f="38132" txt_i="22411" txt_f="22478"> compared with placebo regardless of age, gender, baseline BMI, HbA</offsets><sub><offsets xml_i="38137" xml_f="38139" txt_i="22478" txt_f="22480">1c</offsets></sub><offsets xml_i="38145" xml_f="38216" txt_i="22480" txt_f="22551"> and FPG. Vildagliptin was efficacious irrespective of the baseline HbA</offsets><sub><offsets xml_i="38221" xml_f="38223" txt_i="22551" txt_f="22553">1c</offsets></sub><offsets xml_i="38229" xml_f="38379" txt_i="22553" txt_f="22703">. Greater reduction was seen in patients with higher baseline, which is consistent with the results observed in a predominantly Caucasian population [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="38412" xml_f="38414" txt_i="22703" txt_f="22705">11</offsets></xref><offsets xml_i="38421" xml_f="38423" txt_i="22705" txt_f="22707">].</offsets></p><p><offsets xml_i="38430" xml_f="38527" txt_i="22708" txt_f="22805">Approximately one-third of patients treated with vildagliptin (30.9%) achieved the predefined HbA</offsets><sub><offsets xml_i="38532" xml_f="38534" txt_i="22805" txt_f="22807">1c</offsets></sub><offsets xml_i="38540" xml_f="38624" txt_i="22807" txt_f="22891"> target of ≤6.5%. Furthermore, almost two-thirds of patients (64.1%) reached the HbA</offsets><sub><offsets xml_i="38629" xml_f="38631" txt_i="22891" txt_f="22893">1c</offsets></sub><offsets xml_i="38637" xml_f="38711" txt_i="22893" txt_f="22964"> target of &lt;7.0%, a goal recommended by the Japanese Diabetes Society [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="38743" xml_f="38744" txt_i="22964" txt_f="22965">6</offsets></xref><offsets xml_i="38751" xml_f="38863" txt_i="22965" txt_f="23074">]. The responder rate (&lt;7.0%) was higher than that reported in a predominantly Caucasian population (55.4%) [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="38896" xml_f="38898" txt_i="23074" txt_f="23076">11</offsets></xref><offsets xml_i="38905" xml_f="38959" txt_i="23076" txt_f="23130">]. Over half of the population (57.4%) achieved an HbA</offsets><sub><offsets xml_i="38964" xml_f="38966" txt_i="23130" txt_f="23132">1c</offsets></sub><offsets xml_i="38972" xml_f="39071" txt_i="23132" txt_f="23231"> reduction of ≥1.0%, and 86.8% of patients reported a reduction of ≥0.5% in the vildagliptin group.</offsets></p><p><offsets xml_i="39078" xml_f="39161" txt_i="23232" txt_f="23315">Vildagliptin showed statistically significant reduction in FPG levels vs. placebo (</offsets><italic><offsets xml_i="39169" xml_f="39170" txt_i="23315" txt_f="23316">P</offsets></italic><offsets xml_i="39179" xml_f="39543" txt_i="23316" txt_f="23677"> &lt; 0.001) as add-on to metformin monotherapy after 12 weeks of treatment. The decrease in FPG could be attributed to increased active levels of GLP-1 upon twice-daily administration of vildagliptin 50 mg, which enhances insulin secretion and suppresses glucagon levels relative to glucose levels, in turn decreasing the endogenous glucose production overnight [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="39576" xml_f="39578" txt_i="23677" txt_f="23679">21</offsets></xref><offsets xml_i="39585" xml_f="39587" txt_i="23679" txt_f="23681">].</offsets></p><p><offsets xml_i="39594" xml_f="39867" txt_i="23682" txt_f="23955">Overall, vildagliptin added to metformin was safe with no new safety findings observed in Japanese patients with T2DM. The observed safety profile was similar with previously reported 52-week safety study of vildagliptin add-on to metformin in Japanese patients with T2DM [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="39900" xml_f="39902" txt_i="23955" txt_f="23957">22</offsets></xref><offsets xml_i="39909" xml_f="40005" txt_i="23957" txt_f="24053">], long-term study of vildagliptin add-on to metformin in a predominantly Caucasian population [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="40038" xml_f="40040" txt_i="24053" txt_f="24055">23</offsets></xref><offsets xml_i="40047" xml_f="40132" txt_i="24055" txt_f="24140">], and safety pooled analysis of vildagliptin studies of ≥12 to ≥104 weeks duration [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="40165" xml_f="40167" txt_i="24140" txt_f="24142">24</offsets></xref><offsets xml_i="40174" xml_f="40471" txt_i="24142" txt_f="24439">]. Four patients in the vildagliptin group and one patient in the placebo group reported clinically asymptomatic mild elevations of amylase and/or lipase; however, none of these cases were considered as an AE of acute pancreatitis by the investigators. Similar to the previously reported studies [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="40504" xml_f="40506" txt_i="24439" txt_f="24441">25</offsets></xref><offsets xml_i="40513" xml_f="40620" txt_i="24441" txt_f="24548">], treatment with vildagliptin as add-on to metformin confirmed its weight neutrality in Japanese patients.</offsets></p><p><offsets xml_i="40627" xml_f="40792" txt_i="24549" txt_f="24714">There were no incidences of hypoglycemia reported in the study. Absence of hypoglycemic events in the vildagliptin group, in spite of lower mean baseline FPG and HbA</offsets><sub><offsets xml_i="40797" xml_f="40799" txt_i="24714" txt_f="24716">1c</offsets></sub><offsets xml_i="40805" xml_f="40836" txt_i="24716" txt_f="24747"> levels than the global study [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="40869" xml_f="40871" txt_i="24747" txt_f="24749">11</offsets></xref><offsets xml_i="40878" xml_f="41233" txt_i="24749" txt_f="25104">], confirms the glucose-dependent action of vildagliptin. This is consistent with the results from a previously reported large pooled analysis of global safety data, which showed that vildagliptin, as monotherapy or in combination with metformin, thiazolidinedione, or sulfonylurea, is associated with fewer hypoglycemic events compared with comparators [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="41266" xml_f="41268" txt_i="25104" txt_f="25106">24</offsets></xref><offsets xml_i="41275" xml_f="41277" txt_i="25106" txt_f="25108">].</offsets></p><p><offsets xml_i="41284" xml_f="41329" txt_i="25109" txt_f="25154">The notable benefit observed in improving HbA</offsets><sub><offsets xml_i="41334" xml_f="41336" txt_i="25154" txt_f="25156">1c</offsets></sub><offsets xml_i="41342" xml_f="41692" txt_i="25156" txt_f="25506"> levels confirms the complementary mechanism of action of vildagliptin and metformin in Japanese patients with T2DM. Metformin increases the plasma concentration of incretin hormones and enhances the effects of DPP-4 inhibition on the increase of intact GLP-1, which might explain the improved efficacy of vildagliptin in combination with metformin [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="41725" xml_f="41727" txt_i="25506" txt_f="25508">26</offsets></xref><offsets xml_i="41734" xml_f="41736" txt_i="25508" txt_f="25510">].</offsets></p><p><offsets xml_i="41743" xml_f="41832" txt_i="25511" txt_f="25600">In conclusion, vildagliptin 50 mg bid as add-on to metformin is effective in reducing HbA</offsets><sub><offsets xml_i="41837" xml_f="41839" txt_i="25600" txt_f="25602">1c</offsets></sub><offsets xml_i="41845" xml_f="41990" txt_i="25602" txt_f="25747"> and FPG levels without any tolerability issues and hypoglycemia in Japanese patients with T2DM inadequately controlled on metformin monotherapy.</offsets></p></sec><sec sec-type="supplementary-material"><sec id="Sec14"><title><offsets xml_i="42062" xml_f="42095" txt_i="25749" txt_f="25782">Electronic supplementary material</offsets></title><p><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13300_2014_59_MOESM1_ESM.pdf"><caption><p><offsets xml_i="42229" xml_f="42266" txt_i="25783" txt_f="25820">Supplementary material 1 (PDF 209 kb)</offsets></p></caption></media></supplementary-material></p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec13"><title>List of investigators/institutions</title><p>Akira Numata (Ikebukuro Metropolitan Clinic), Hideki Hanashi (New Medical Research System Clinic), Otoya Miho (Miho Clinic), Munechika Noguchi (Shinagawa East One Medical Clinic), Hideki Kaizuka (Pedi Shiodome Clinic), Nobuki Wakao (KASAI Diabetes Clinic), Takashi Lizuka (Asahi Medical Clinic), Tatsuhiro Shimoyama (Shimamura Kinen Hospital), Hiroshi Shimomura (Musashino Polyclinic), Masafumi Sugawara (Dyna Medical Nezu Clinic), Shizuo Kajiyama (Medical Corporation Keisei-kai Kajiyama Clinic), Seiichi Tanaka (Kyushu Rosai Hospital), Yasuhiro Sako (Saiseikai Fukuoka General Hospital), Kiyohide Nunoi (St. Mary’s Hospital), Yasuhiro Ono (Takagi Hospital), Makoto Kunisaki (Kunisaki Makoto Clinic), Shizuka Kaneko (Takatsuki Red Cross Hospital), Ryuji Suzuki (Kawasaki Suzuki Medical Clinic), Tomio Inoue (Ageo Central General Hospital) and Kentaro Doi (Rakuwakai Otowa Hospital).</p></sec></app></app-group><fn-group><fn><p>Trial registration: Clinical Trials.gov #NCT01497522.</p></fn></fn-group><ack><p>The authors would like to thank the patients and staff who participated in this study. Sponsorship and article processing charges for this study were funded by Novartis Pharma K.K. The authors take full responsibility for the content of the manuscript and participated at all stages of manuscript development and approved the final manuscript for publication. Masato Odawara and Manabu Suzuki contributed to study design, data analysis and interpretation and contributed to drafting of the manuscript. Izumi Hamada provided support for statistical analysis. All authors meet the ICMJE criteria for authorship, had full access to the study data and take complete responsibility for the integrity of the data and accuracy of the data analysis. Medical writing assistance, editorial assistance, and collation and incorporation of comments from all authors for this study were provided by Anuja Shah (Novartis Healthcare Pvt. Ltd., Hyderabad, India) and Amit Garg (Novartis Healthcare Pvt. Ltd., Hyderabad, India).</p><sec id="d30e1889"><title>Conflict of interest</title><p>Manabu Suzuki is an employee of Novartis Pharma K.K. Izumi Hamada is an employee of Novartis Pharma K.K. Masato Odawara is the independent medical advisor for this study and has received consultancy fees from Novartis Pharma K.K.</p></sec><sec id="d30e1894"><title>Compliance with ethics guidelines</title><p>The study protocol was reviewed and approved by the Independent Ethics Committee/Institutional Review Board at each center. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), the Helsinki Declaration of 1975, as revised in 2000 and 2008 and Good Clinical Practice guidelines. Informed consent was obtained from all patients for being included in the study.</p></sec><sec id="d30e1899"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium: International Diabetes Federation; 2011. <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas/5e/diabetes">http://www.idf.org/diabetesatlas/5e/diabetes</ext-link>. Accessed Aug 5, 2013.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamori</surname><given-names>R</given-names></name></person-group><article-title>Diabetes trends in Japan</article-title><source>Diabetes Metab Res Rev</source><year>2002</year><volume>18</volume><fpage>S9</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.1002/dmrr.296</pub-id><pub-id pub-id-type="pmid">12324979</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>SE</given-names></name><name><surname>Boye</surname><given-names>KS</given-names></name><name><surname>Montgomery</surname><given-names>WS</given-names></name><name><surname>Iwamoto</surname><given-names>K</given-names></name><name><surname>Okamura</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>RP</given-names></name></person-group><article-title>Diabetes in Japan: a review of disease burden and approaches to treatment</article-title><source>Diabetes Metab Res Rev</source><year>2009</year><volume>25</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1012</pub-id><pub-id pub-id-type="pmid">19795421</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Usami</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes</article-title><source>Metabolism</source><year>2004</year><volume>53</volume><fpage>831</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2004.02.012</pub-id><pub-id pub-id-type="pmid">15254872</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Japan Diabetes Clinical Data Management Study Group. HbA1c (NGSP) in 2008. Ibaraki. <ext-link ext-link-type="uri" xlink:href="http://jddm.jp/data/index.html">http://jddm.jp/data/index.html</ext-link>. Accessed Aug 10, 2013.</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Japan Diabetes Society, Treatment Guide for Diabetes edited by Japan Diabetes Society 2012–2013. Bunkodo Co. Ltd.; 2013.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirpichnikov</surname><given-names>D</given-names></name><name><surname>McFarlane</surname><given-names>SI</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>Metformin: an update</article-title><source>Ann Intern Med</source><year>2002</year><volume>137</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-137-1-200207020-00009</pub-id><pub-id pub-id-type="pmid">12093242</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrén</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Bosi</surname><given-names>E</given-names></name></person-group><article-title>Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01321.x</pub-id><pub-id pub-id-type="pmid">21205107</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrén</surname><given-names>B</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name><name><surname>Villhauer</surname><given-names>EB</given-names></name><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name></person-group><article-title>Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><fpage>775</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01414.x</pub-id><pub-id pub-id-type="pmid">21507182</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Mills</surname><given-names>D</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name></person-group><article-title>Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes</article-title><source>Diabetes Res Clin Pract</source><year>2007</year><volume>76</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2006.12.009</pub-id><pub-id pub-id-type="pmid">17223217</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Camisasca</surname><given-names>RP</given-names></name><name><surname>Collober</surname><given-names>C</given-names></name><name><surname>Rochotte</surname><given-names>E</given-names></name><name><surname>Garber</surname><given-names>AJ</given-names></name></person-group><article-title>Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.2337/dc06-1732</pub-id><pub-id pub-id-type="pmid">17277036</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>AJ</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Banerji</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea</article-title><source>Diabetes Obes Metab</source><year>2008</year><volume>10</volume><fpage>1047</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2008.00859.x</pub-id><pub-id pub-id-type="pmid">18284434</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>AJ</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Baron</surname><given-names>MA</given-names></name><name><surname>Rochotte</surname><given-names>E</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name></person-group><article-title>Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study</article-title><source>Diabetes Obes Metab</source><year>2007</year><volume>9</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00684.x</pub-id><pub-id pub-id-type="pmid">17300592</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothny</surname><given-names>W</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Kozlovski</surname><given-names>P</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name><name><surname>Lukashevich</surname><given-names>V</given-names></name></person-group><article-title>Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1111/dom.12020</pub-id><pub-id pub-id-type="pmid">23039321</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Terao</surname><given-names>S</given-names></name><name><surname>Mimori</surname><given-names>N</given-names></name><name><surname>Tachibana</surname><given-names>H</given-names></name></person-group><article-title>Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus</article-title><source>Diabetes Res Clin Pract</source><year>2009</year><volume>83</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2008.10.006</pub-id><pub-id pub-id-type="pmid">19118913</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Kashiwagi</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of vildagliptin and voglibose in Japanese patients with Type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study</article-title><source>Diabetes Obes Metab</source><year>2010</year><volume>12</volume><fpage>700</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01222.x</pub-id><pub-id pub-id-type="pmid">20590747</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Dotta</surname><given-names>F</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Goodman</surname><given-names>M</given-names></name></person-group><article-title>Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2009.01040.x</pub-id><pub-id pub-id-type="pmid">19320662</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Odawara</surname><given-names>M</given-names></name><name><surname>Nishii</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Ferreira</surname><given-names>JCA</given-names></name></person-group><article-title>Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks</article-title><source>J Diabetes Investig</source><year>2013</year><volume>4</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1111/jdi.12001</pub-id><pub-id pub-id-type="pmid">24843649</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seino</surname><given-names>Y</given-names></name><name><surname>Miyata</surname><given-names>Y</given-names></name><name><surname>Hiroi</surname><given-names>S</given-names></name><name><surname>Hirayama</surname><given-names>M</given-names></name><name><surname>Kaku</surname><given-names>K</given-names></name></person-group><article-title>Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2012.01620.x</pub-id><pub-id pub-id-type="pmid">22583697</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>N</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Murai</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1111/dom.12110</pub-id><pub-id pub-id-type="pmid">23565760</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balas</surname><given-names>B</given-names></name><name><surname>Baig</surname><given-names>MR</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1882</pub-id><pub-id pub-id-type="pmid">17244786</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Odawara M, Suzuki M, Hamada I, Iguchi A. Clinical evaluations of the vildagliptin combination therapy in type 2 diabetes patients – A long term safety study of 52 weeks treatment with vildagliptin as add-on therapy with metformin, TZD, α-GI or Glinides. J New Rem Clin. 2012;12:2593–611 (article in Japanese).</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name><name><surname>Ahrén</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study</article-title><source>Diabetes Obes Metab</source><year>2010</year><volume>12</volume><fpage>780</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01233.x</pub-id><pub-id pub-id-type="pmid">20649630</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Kothny</surname><given-names>W</given-names></name></person-group><article-title>Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies</article-title><source>Vasc Health Risk Manag</source><year>2011</year><volume>7</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2147/VHRM.S16925</pub-id><pub-id pub-id-type="pmid">21415917</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Jordan</surname><given-names>J</given-names></name></person-group><article-title>Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience</article-title><source>Vasc Health Risk Manag</source><year>2010</year><volume>6</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">20730070</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migoya</surname><given-names>EM</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name><etal></etal></person-group><article-title>Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>88</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.184</pub-id><pub-id pub-id-type="pmid">21048706</pub-id></element-citation></ref></ref-list></back></article>